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Abstract

A STUDY OF COVERAGE OPTIMIZED PLANNING INCORPORATING MODELS OF
GEOMETRIC UNCERTAINTIES FOR PROSTATE CANCER
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A fundamental challenge in the treatment planning process of multi-fractional externalbeam radiation therapy (EBRT) is the tradeoff between tumor control and normal tissue sparing
in the presence of geometric uncertainties (GUs). To accommodate GUs, the conventional way
is to use an empirical planning treatment volume (PTV) margin on the treatment target.
However, it is difficult to determine a near-optimal PTV margin to ensure specified target
coverage with as much normal tissue protection as achievable.
Coverage optimized planning (COP) avoids this problem by optimizing dose in possible
virtual treatment courses with GU models directly incorporated. A near-optimal dosimetric
margin generated by COP was reported to savvily accommodate setup errors of target and
normal tissues for prostate cancer treatment.

xxiv

This work further develops COP to account for (1) deformable organ motion and
(2) delineation uncertainties for high-risk prostate cancer patients. The clinical value of COP is
investigated by comparing with two margin-based planning techniques: (i) optimized
margin (OM) technique that iteratively modifies PTV margins according to the evaluated target
coverage probability and (ii) fixed margin (FM) technique that uses empirically selected constant
PTV margins.
Without patient-specific coverage probability estimation, FM plans are always less
immune to the degraded effect of the modeled GUs than the COP plans or the OM plans.
Empirical PTV margins face more risks of undesirable target coverage probability and/or
excessive dose to surrounding OAR.
The value of COP relative to OM varies with different GUs. As implemented for
deformable organ motions, COP has limited clinical benefit. Due to optimization tradeoffs, COP
often results in target coverage probability below the prescribed value while OM achieves better
target coverage with comparable normal tissue dose. For delineation uncertainties, the clinical
value of COP is potentially significant.

Compared to OM, COP successfully maintains

acceptable target coverage probability by exploiting the slack of normal tissue dose in low dose
regions and maximally limiting high dose to normal tissue within tolerance.
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Introduction

In external radiation therapy (EBRT), desirable treatment techniques allow tumoricidal
dose coverage to malignant tumor cells with dose sparing of normal tissues. Geometric
uncertainties (GUs) involved in multi-fractional treatment delivery constrain the available
solution space. The conventional way to accommodate GUs, called margin-based planning
techniques, uses margins to create expanded volumes as surrogates of regions of interest (ROIs).
(ICRU Report 50 1994) This technique inherently assumes that the ROI under the influence of
GUs can occupy any location within the expanded volume with equal probability, which may not
be true in real cases. Inadequate margin selection may cause poor dose coverage or excessive
toxicity to normal tissues.

While advanced technologies for target localization and plan

adaptation aim to reduce GUs, they are not yet included in the clinical routine. An intermediate
solution can be found by using a technique called probabilistic treatment planning (PTP). PTP
directly incorporates models of GUs into treatment planning and results in margins customized
to the GUs and the orientation of the patient anatomy. As a new frame work of PTP, coverage
optimized planning (COP) was tested to give desirable treatment plans for prostate cancer in the
presence of setup errors and shows some potential as an alternative to the margin-based planning
technique. (Gordon et al. 2010) This dissertation further develops COP to explicitly incorporate
other GUs using appropriate mathematical models. Virtual clinical trials are performed to assess
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the hypothesis that COP produces more desirable plans than those planning techniques that use
margin-based surrogate volumes.
Chapter 1 describes some background knowledge of GUs involved in EBRT for prostate
cancer (1.1) and evolved treatment planning techniques to consider these GUs (1.1.2). In 1.3, the
purposes and the outline for the following chapters (2-0) of this dissertation are given.
1.1 Introduction to GUs in external beam radiation therapy
1.1.1

External beam radiation therapy for prostate cancer

Prostate cancer1 is the third most common cause of death from cancer in men of all ages.
In 2012, there were about 242,000 new cases of prostate cancer in the United States. (National
Cancer Institute (NCI) booklet, 2012) With the widespread use of prostate-specific antigen
(PSA) screening, radiation therapy (RT) has become a primary treatment for the patients with
clinically localized disease. As the National Comprehensive Cancer Network (NCCN) treatment
guidelines specified, patients in low, intermediate or high risk groups (Table I) may be treated
with RT for therapeutic management.
Table I. NCCN Risk Groupings on prostate cancer staging (T1-T4) and PSA. (National Comprehensive
Cancer Network (NCCN Clinical Practice Guidelines in Oncology v.1.2005)
Low risk:
Intermediate risk:
High risk:

T1-T2a, PSA < 10 ng/mL
T2b-T2c, PSA 10-20 ng/mL
T3-T4, PSA > 20 ng/mL

External beam radiation therapy (EBRT) is one of the most common forms of RT for
prostate cancer treatment. When a patient lies on a couch, EBRT directs high doses of radiation
from a source outside patient body to a particular part of body (Figure 1). With a long history,
EBRT has been developed into several advanced delivery modes such as intensity modulated
1

Note, prostate cancer is studied as a “test bench” in this dissertation. There are no exclusions for the other
interesting clinical sites.
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radiation therapy (IMRT).

IMRT takes the advantage of multi-leaf collimators to produce

customized radiation fluence (Figure 2), thereby allowing high-precision radiation doses to be
focused to regions to of regular or irregular shaped targets.

Figure 1. EBRT for prostate cancer treatment. (adapted from Patient Health International, ©
AstraZeneca 2012)

Figure 2: A sketch of fluence intensity of 3 beams in an IMRT for prostate cancer treatment. High beam
intensity (and therefore high dose) is delivered to the target prostate (red) and low beam intensity (and
low dose) is delivered to the surrounding bladder (yellow) and rectum (magenta).

However, like the other treatment modalities, EBRT is far from perfect even with the
advanced modes. The ultimate goal of EBRT is to deliver a prescribed dose to treat targets (i.e.
malignant cells) with as low as possible toxic irradiation to the surrounding normal tissues.
3

According to a clinical outcome review (Cahlon et al. 2008) on 478 prostate cancer patients
treated with 86.4 Gy2 using a 5- to 7-field IMRT technique, the 5-year actuarial PSA relapse-free
survival according to the nadir plus 2 ng/mL definition was 98%, 85% and 70% for the low,
intermediate, and high risk NCCN prognostic groups, respectively.

The normal tissue

complication, such as Grade 2 genitourinary toxicity and acute Grade 2 gastrointestinal toxicity
that associated with bladder toxicity and rectal bleeding, was experienced by 22% and 8%
patients. The improvement of tumor control rate is still limited by treatment complications to
surrounding normal tissues.
EBRT is composed of multiple processes: problems in any process could prevent the
destruction of all the cancer cells or excessively damaging normal tissues. The flow of EBRT is
as follows. First, the cancer is staged and a therapeutic decision is made for the patient. When
EBRT is chosen, the patient is imaged to quantify the location and volume of tumor and
surrounding normal tissues. Often, to better align the target, fiducial markers are inserted into
prostate before patient being imaged. Based on the imaging data, the treatment target and
normal tissue structures are delineated. A computerized treatment planning system (TPS) is then
used to design a treatment plan on the patient image. Treatment parameters such as treatment
volume, dose prescription and external beam arrangement are determined. During the IMRT
inverse planning (See chapter 2, section 2.1), the dose distribution is calculated and optimized
until it satisfies a specific set of dose objectives. The treatment delivery is then simulated for
quality assurance purposes prior to the treatment. During the treatment course, the prescribed
dose is delivered in multiple treatment fractions on separate days. (For instance, total dose 78
Gy for a patient may be delivered in fractions of 2 Gy on each of five day per week over 8
2

Gy is dose unit used in this dissertation. 1 Gy = absorbed energy (associated with ionizing radiation)
deposited per unit mass of irradiated tissue. 1Gy = 1J/kg.
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weeks.) The treatment is fractionated with the purpose of e.g., allowing repair of cellular
damage for normal tissues based on radiobiological principles. (See section 3.3.1 of chapter 3
for more details of cellular response to fractionated dose.) Obviously, the uncertainties involved
in each stage of the EBRT can impact the final treatment outcome. Within the scope of this
dissertation, a particular attention is paid to how GUs can be addressed during the EBRT
treatment planning process.
1.1.2

GUs and their models

To improve the probability of achieving the therapeutic intent of treatment, GUs should
be considered adequately during the treatment planning. GUs introduce deviations between the
planned (intended) and the treatment geometry, which, if inadequately accounted for, could
result in undesirable target dose coverage and/or more normal tissue toxicity. This problem is
especially significant for IMRT, as miss-aligned conformal dose distribution may be more likely
miss the intended target. Moreover, GUs are mostly unavoidable and not easy to predict. To
achieve desirable treatment outcomes, a specified knowledge of GUs caused by each process of
external beam radiation therapy is essential for planning purposes (Wilkinson 2004).
The standard method of accommodating GUs is to define various treatment volumes as
recommended by the International Commission on Radiation Units and Measurements report
(ICRU) reports. (ICRU Report 50 1994, ICRU Report 62 2000, ICRU Report 83 2011) These
volumes aid the current planning process for the consideration of GUs.

A schematic

representation of these volumes is shown in Figure 3.
The targets for treatment purpose are called the clinical target volume (CTV), which
consists of the gross tumor volume (GTV) that is visible through the employed image modalities
and suspected anatomical spread disease. In order to absorb the GUs associated with the CTV,
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the planning target volume (PTV) is defined. The distance between the CTV and PTV is termed
the CTV-to-PTV margin. This margin is expected to be large enough to ensure clinically
acceptable probability of CTV coverage when the PTV dose distribution serves as a surrogate of
the CTV dose distribution. For normal tissues, an organ at risk (OAR) is defined as “the normal
tissues whose radiation sensitivity may significantly influence treatment planning and/or
prescribed dose”. (ICRU Report 50 1994) The critical OARs for prostate cancer patients include
the bladder, the rectum, the femurs and small bowel if within the primary beam aperture. The
recent ICRU 83 report (ICRU Report 83 2011) articulates that the bladder wall and rectal wall
should be used to explicitly exclude the inside content for the bladder and rectum. However, use
of bladder/rectal wall structures is not yet routine clinical practice. In analogy with the PTV, the
concept of the planning organ at risk volume (PRV) is introduced (ICRU Report 62 2000) to take
into account the GUs of the OAR by adding margins. Clinically, PRVs are rarely used.

Figure 3: Schematic representations of relationship between volumes GTV, CTV, PTV for target
structures and OAR, PRV for surrounding normal tissues.

GUs to be accounted for in the CTV-to-PTV margin or the OAR-to-PRV margin can be
categorized as (1) setup errors, (2) delineation uncertainties, (3) interfraction and (4) intrafraction
variations in structure position shape and size. Setup errors (Figure 4a) are deviations in the
positioning and alignment of patient (where the coordinate system of GTV, CTV and OAR are)
6

with respect to therapeutic beams (the accelerator coordinate system in which PTV and PRV
exist). Delineation uncertainties refer to the deviations (between different observations, or
between the indicated value and the true value) on the location of the interface between target
and adjacent tissues. The sources of delineation uncertainties include (i) limited image quality of
employed imaging modalities (e.g. poor soft-tissue contrast in CT images), (ii) different clinical
judgment of different observers (inter-observer delineation uncertainties) (Figure 4b.), and (iii)
different clinical judgment of the same observer in different trials (intra-observer delineation
uncertainties). Interfraction variations refer to the day-to-day (fraction-to-fraction) variations in
positions and volumes (and/or shapes) of the region of interest (ROI) in different treatment
fractions.

Intra-fraction variations occur between the completion of setup procedure and

completion of delivery of the intended radiation fraction. Both interfraction and intrafraction
variations are caused by internal organ motion and deformation (Figure 4c).

`
(a)

`` (b)

(c)
Figure 4: Illustration of different types of GUs: (a) setup errors that fail to align patient position to the
beam treatment head of LINAC (linear accelerator), (b) inter-observer delineation uncertainties for the
same structures, (c) organ motion and deformation that may occur between treatment fractions
(interfraction organ variations) or during a single treatment fraction at different treatment fractions
(intrafraction organ variations).
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To incorporate GUs into treatment planning techniques, mathematical models can be very
useful. The following paragraphs review the models developed for each category of GUs.
Setup errors are often modeled in terms of rigid body shifts and rotation. Methods have
been proposed to describe these rigid uncertainties by six translational and rotational parameters.
(Killoran et al. 1997, van Herk et al. 2002, Baum et al. 2004, Gordon et al. 2007) The
probability distributions of these parameters are usually assumed to be Gaussian distributions
(Stroom et al. 1999, Yan et al. 1999, Stroom and Heijmen 2002) and can be derived from a
population or sometimes an estimated patient-specific level retrospectively.
Mathematical models of internal organ motions and deformations, though still evolving,
show some potential in representing realistic interfraction/intrafraction variations.

When it

comes to prostate, building good mathematical models may not be a problem for the following
reasons. Although prostate is surrounded by the rectum (Hoogeman et al. 2004, Adamson and
Wu 2009) and bladder (Meijer et al. 2003), which empty and fill unpredictably to some extent, it
is well known that prostate deforms less than bladder and rectum (Roeske et al. 1995) and
prostate displacement can be reliably tracked using implanted fiducial markers or Calypso
transponders (Calypso, Seattle, WA) on an interfraction (Kupelian et al. 2005, Peng et al. 2010)
and an intrafraction (Langen et al. 2008, Santanam et al. 2009, Bittner et al. 2010) basis. Inroom computed tomography (CT) (Keall 2004, Pouliot 2007, Frank et al. 2008) and cinemagnetic resonance imaging (cine-MRI) scans (Mah et al. 2002, Ghilezan et al. 2005) can also
record anatomy motion and volumetric information. All these techniques provide information
about target motion, from which dosimetric or biological effects can be estimated.

Much

published work (listed in Table II) has described prostate interfraction or intrafraction variations
by constructing mathematical models.
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Table II. Some published models of interfraction, intrafraction variations for prostate, bladder, and rectum.
reference

model

(Fontenla et

method

al. 2001)

statistical

for

reconstructing

distribution

uncertainties

ROI(s)

interfraction motion

Prostate/bladder/rectum

of

(any

organ motion

site

with

serial

measurement)

(Söhn et al.

individual-based

principal

2005a)

component analysis (PCA)

interfraction deformation

Prostate

+

bladder

+

of structure surface

rectum for prostate caner

interfraction motion and

Prostate + seminal vesicles

deformation of voxels

for prostate cancer

model
(Budiarto et

population-based PCA model

al. 2011)
(Chow et al.

Gaussian error function for

interfraction

2009)

cumulative

prostate shifting in AP

DVH

for

motion

planning evaluation

direction

(Jeong et al.

bilinear model to capture and

inter-

2010)

decouple inter- and intra-

shape

patient shape variation of

interfraction motion

organ

A

method

reconstructing

and

of

intra-patient

variation

Prostate/bladder/rectum for
prostate caner
Prostate for prostate cancer

and

for

statistical

distribution of organ motion
(Lotz et al.

linear

2004)

bladder

model
shapes

to

predict

based

on

interfraction motion and

Bladder for bladder cancer

deformation

known urinary inflow and
rectal filling
(Chai et al.

Biomechanical

2011)

predict

model

short-time

to

interfraction motion

bladder

Bladder + 6 surrounding
pelvic organ for bladder

shape with bladder volume as

cancer

input
(Hoogeman

stochastic shape description

et al. 2002)

model with population-based

interfraction deformation

Rectum for prostate cancer

parameters based on dosewall histogram
Abbreviations: ROI = region of interest; DVH = dose volume histogram; AP = anterior-posterior

Mathematical models have also been built for bladder and rectum deformable motion.
Bladder and rectum are known as main drivers of pelvic organs motion (Ten Haken et al. 1991)
and are much more likely to move and deform due to filling than prostate. As OARs, bladder
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and rectum are not as well studied as target prostate, therefore many of their models may be less
optimal than prostate model. For the examples listed in Table II, the linear bladder shape model
(Lotz et al. 2004) is for the bladder as a tumor, not an OAR. The biomechanical model has much
poorer accuracy compared with the higher degree models (Chai et al. 2011). The stochastic
shape description model needs more patients for evaluation (Hoogeman et al. 2002). However,
the principal component analysis (PCA) model (Söhn et al. 2005b) addresses the above
challenges and provides a quantitative description of geometric variability.

Therefore,

interfraction and intrafraction variations can be approximated in a quasi-realistic way by models
like the PCA model.
In contrast, as the “weakest link in the search for accuracy” (Njeh 2008), delineation
uncertainties were rarely modeled.

As there is no verifiable ground truth of the tumor

locations/volume, delineation uncertainties persist even with perfect images. Delineation
uncertainties are usually quantified by difference of repeatedly delineated contours. Though
recent developed auto-contouring tools allows much faster with more consistent contours
between trials, the tedious and time-consuming manual contours are usually still required for
validations and corrections (Huyskens et al. 2009). Based on limited number of manual contours,
most researches have been only focused on evaluation of boundary visualization (Zhou et al.
1998, Rasch et al. 1999, Weiss and Hess 2003, Gao et al. 2007, Weiss et al. 2010) or
development of 3D analysis tools (Remeijer et al. 1999, Korporaal et al. 2010, Wu et al. 2010).
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1.2 Evolution of treatment planning approaches
1.2.1

Margin-based planning

For the current practice of conventional margin-based planning approach, the PTV or
PRV margin given by conventional margin formulas may be suboptimal to account for GUs.
(Note, the PTV/PRV margin is the short name of CTV-to-PTV/OAR-to-PRV margin.) This is
because coverage probability, the probability that desirable dose delivered to a volume is
achieved, is dictated by the dose distribution, not the margins. (Gordon and Siebers 2009) An
inadequate PTV margin, e.g., over-sized, may result in unnecessary irradiation to normal tissues
and cause a higher risk of normal tissue toxicity. Margin size can be optimized using evolving
treatment planning techniques such as the PTP approach. This actively researched approach can
create anisotropic and patient-specific margins on the premise that the probability distribution
function (PDF) of GUs is known. Both margin-based planning approach and PTP approach will
be discussed in the following paragraphs.
While commonly practiced in the planning process for real patient treatments, the
conventional margin-based planning approach faces the obstacle of defining desirable PTV
and/or PRV margins in the presence of GUs. Numerous margin recipes (or guidelines) (Stroom
et al. 1999, van Herk et al. 2000, McKenzie et al. 2002, van Herk 2004) were published to
determine PTV margins, but no gold standard/consensus of recipe/guideline is clinically used for
margin-based planning, whose planning objectives includes uniform dose to PTV volumes.
Two problems in the current margin recipes/guidelines are likely to be involved in the
margin-based planning approach. The first problem is that the PTV margin derived from a
population-based model cannot ensure patient-specific coverage in the presence of GUs. Use the
most commonly used recipe — van Herk margin formula (van Herk et al. 2000) — as an
11

example.

With the intention to guarantee that 90% of patients in a population receive a

minimum cumulative CTV dose of at least 95% of the prescribed dose, this margin formula is
approximately 2.5 times the total standard deviation (SD) of the systematic errors (which shift
structures relative to the cumulative dose distribution) and 0.7 times the total SD of the random
errors (which blur the cumulative dose distribution). The errors in convolution are assumed to
follow a Gaussian distribution. The assumption of Gaussian-distributed errors may be not
adequate for GUs such as prostate deformation (Deurloo et al. 2005), especially given that
prostate is surrounded with the rectum (Hoogeman et al. 2004, Adamson and Wu 2009) and
bladder (Meijer et al. 2003) which empty and fill unpredictably to some extent. Even if GUs are
Gaussian distributed, the assumptions of population statistics being representative to individual
patient are questionable. Setup errors are frequently believed to follow a Gaussian distribution
approximately (Stroom et al. 1999, Yan et al. 1999, Stroom and Heijmen 2002). However, if
one considers setup errors only, and uses margins based on population statistics (i.e. SD of setup
or random errors) derived from the van Herk formula (van Herk et al. 2000), recent research
(Gordon and Siebers 2008) showed no one-to-one relationship between PTV and target coverage.
Patient-specific characteristics such as anatomy geometry (Yan et al. 1997) are too complicated
to be summarized in a simple equation/guideline. Consequently, the patient-specific coverage
probabilities for both target and OARs may vary widely between patients (e.g., 57% - 100% for
prostate prescribed at minimum dose with setup SD 3mm) (Xu et al. 2011). (In practical cases,
population statistics are still utilized, although they are necessarily approximate.) The second
problem in margin recipes/guidelines is that margins are not ideally suited to balance the tradeoff
of CTV coverage and OAR toxicity. During treatment planning, each voxel inside a PTV (in the
accelerator coordinate system) is naively assumed equally important for CTV (in patient
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coordinate system). For adjacent organs, often consideration of uncertainties yields situations
where the PTV and OAR/PRV overlaps, yielding a paradox for a plan optimization algorithm.
Competition between PTV and OAR criteria may end up with an unacceptable solution since
shaving margins in some direction to avoid the overlap does not necessarily result in an
acceptable tradeoff between target coverage and OAR sparing. These limitations potentially
prevent the conventional margin-based planning approach from best accommodating GUs effect
on the patient treatment plan.
1.2.2

Probabilistic treatment planning

Probabilistic treatment planning (PTP) has been studied as a potential replacement of
margin-based planning approach that ameliorates the problems of margin definition.

This

evolving planning approach requires explicit specification of GUs (e.g., GU models and PDF)
and directly incorporates GU information into planning optimization.

Governed by the

probabilistic planning criteria, the treatment planning system (TPS) builds a dose distribution to
achieve the desired coverage probability. Therefore, PTP does not require prior specification of
margin-based volumes (i.e. the PTV and the PRV) but allows direct determination of probable
dose coverage in the presence of GUs. Recent publications addressed different PTP approaches.
These approaches can be classified into two categories: either based on a probability weighted
dose distribution (PWDD), or a probability weighted objective function (PWOF).(Gordon et al.
2010) The PWDD technique is to optimize dose distribution in terms of e.g., dose expectation
values (Löf et al. 1998) alone or with dose variance together (Unkelbach and Oelfke 2004,
2005a, 2005b, Maleike et al. 2006), or the treatment course generated by fluence convolution
(Moore et al. 2009). The PWOF method uses objective functions with probabilistic weights in
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terms of e.g., voxel likelihood (Baum et al. 2006) or biological quantities3 such as equivalent
uniform dose (EUD) (Yang et al. 2005), TCP and NTCP (Witte et al. 2007). Despite the
difference, most PTP studies share a common conclusion: PTP approaches can reduce dose of
OARs without compromise of the highly conformal dose to targets, even though the GUs being
incorporated are approximated.
1.2.3

Coverage optimized planning

The COP framework (Gordon et al. 2010) is another PTP framework. The principle of
COP is described in chapter 2.

Analogous to the dose volume histogram (DVH) criteria

popularly used in other planning approaches, COP utilizes percentile dose volume histogram
(pDVH) criteria for optimization. These criteria aim to achieve adequate target prescription dose
and avoid exceeding OAR tolerance for a specified percentage of GUs. The plan optimization in
COP is based on dose coverage probabilities, as opposed to static dose in conventional marginbased planning.
To date, COP has only been used to compensate setup errors of prostate cancer treatment.
Like the other PTP approaches, COP demonstrated better OAR dose sparing and lower NTCP
values without sacrificing target dose coverage and TCP values using the PDVH criteria for the
target and the OARs. (Gordon and Siebers Unpublished) With the target pDVH criteria alone,
COP can improve target coverage probability while maintaining OAR dose within the tolerance.
(Gordon et al. 2010) To explore the application of COP, it is necessary to develop COP
approach for delineation uncertainties, organ deformable motions of prostate, bladder and rectum
for prostate cancer patients. Due to the fact that the treatment delivery effort of COP is not
different from a margin-based planning, if COP can reduce normal tissue doses without
3

Please refer to chapter 3.3 for details of these biological quantities.
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compromising target coverage for these GUs, it should be cost beneficial to be regarded as a
promising alternative of the margin-based planning.
1.2.4

COP in different clinical scenarios

The dosimetric benefit of COP may vary with different clinical strategies for target
localization and adaptive replanning in EBRT. These gradually maturing advanced strategies
include image-guided radiation therapy (IGRT), adaptive radiotherapy (ART) and their
collaboration—image-guided adaptive radiation therapy (IGART).

The purpose of these

strategies is to reduce uncertainties and/or adapt radiation treatment to individual patient
variations.

IGRT localizes target areas during treatment by using a variety of imaging

techniques in the treatment room.

ART periodically adjusts the treatment to account for

anticipated or observed variations (i.e., translations, rotations and deformations) of targets and
critical structures.

IGART uses individual patient dynamic or time-serial four-dimensional

treatment history, ambitiously to allow dose evaluation and modification on a patient-specific
basis with a frequency as often as treatment-day-specific.
The cost for each strategy could be (a) potentially excessive radiation exposure
introduced by the IGRT imaging methods using cone-beam imaging technology with kilovoltage
(kV) or megavoltage (MV) X rays for CTV positioning (Ding et al. 2008), (b) low efficiency of
ART for plan modification due to excessive clinical work such as quality assurance (QA) effort
and plan approval (Li et al. 2011), and (c) technical challenges of contemporary IGART
including a general lack of a comprehensive QA procedure. (Timmerman and Xing 2009)
Despite the cost, IGRT, ART and IGART are considered to be promising for clinical use due to
their resulting benefits (de Crevoisier et al. 2005, Ghilezan et al. 2010, Lagrange and de
Crevoisier 2010). Recently, the clinical evidence has been reported that adaptive IGRT “appears
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to reduce the risk of geometric miss and results in good biochemical control that is independent
of rectal volume at the time of simulation while maintaining low rates of toxicity.” (Park et al.
2012) Before becoming routine procedure in the clinic, these strategies need more clinical
evidence to demonstrate their benefit and cost.
Image guidance and adaptive replanning due to these strategies will reduce the magnitude
of GUs and perhaps inherent uncertainties such as delineation uncertainties as well.
Consequently, when IGRT, ART and IGART become clinical realities, the potential role of COP
will be to account for residual uncertainties. The benefit of COP relative to margin-based
planning approaches may be less pronounced because of i.e., the negligible size of residual
uncertainties. As a potential intermediate solution before the widespread of the advanced clinical
strategies, COP is expected to either reduce normal tissue doses for the same target coverage or
enable better target coverage with same normal tissue doses with respect to margin-based
planning.
1.3

Thesis Objectives and Outlines

The objectives of this dissertation are to (1) construct mathematical models for GUs
including (i) interfraction organ deformable motions with prostate centroid alignment and
(ii) delineation uncertainties of prostate, bladder and rectum, (2) create COP plans with GU
model incorporated to accommodate these uncertainties and (3) research the clinical value of
COP in the scenarios with/ without advanced strategies by comparing with plans generated by
using two margin-based planning techniques.
The outline of this dissertation is described here. The principle of COP and how COP is
implemented in a commercial TPS are stated in chapter 2. Treatment planning metrics utilized in
this dissertation to quantify dosimetric effect of GUs and compare COP and two different PTV
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plans are covered in chapter 3. Some general materials and methods used in the COP studies are
described in chapter 4. For multi-fractional treatment for prostate cancer, COP plans with
incorporated interfraction deformable organ motion (chapter 5) or delineation uncertainties
(chapter 6) are compared with the parallel PTV plans. In chapter 7, the clinical value of COP
based on results in chapter 5 and 6 is discussed and concluded and further directions of COP
studies are suggested.
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2

The principle of coverage optimized planning

COP is a framework of PTP and a modified IMRT approach. This chapter reviews the
principle of COP and its implementation in a commercial TPS.

The principle of IMRT,

mathematics of different type of objective functions corresponding to different optimization
criteria and how they work in a TPS are also given here.
2.1 From IMRT to COP
The idea of IMRT is to treat a patient using beams of non-uniform fluences from a number
of different directions (or a continuous arc) to plan and deliver a dose distribution to enable
conformal high dose to target volumes and acceptably low dose to the OARs (A simple example
was shown in Figure 2, page 3.) IMRT is an advanced form of three-dimensional conformal
radiotherapy (3D-CRT). As Figure 5 illustrates, both 3D-CRT and IMRT require the planner to
set the beam arrangement (beam angle, energy, and etc.). In 3D-CRT, the planner also has to
decide how to use beam shapers to shapes the resulting radiation. In IMRT, the planner only
needs to specify the treatment criteria (such as what minimum dose delivered to target volumes)
so that the radiation is inversely optimized by TPS. Each beam is automatically shaped by an
MLC and divided into non-equi-weighted segments. The non-uniform beam fluence is inversely
optimized by the objective function algorithm imbedded in TPS to optimally meet all the
treatment criteria. With direct machine parameter optimization, MLC settings are produced
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directly during the optimization process without post process like conversion or filtering which
may degrade the plan quality during dose delivery. Conventionally, the objective functions used
in IMRT are (static) dose-volume based.

Figure 5. An illustration of 3-beam 3D-CRT (left) versus IMRT (right).

COP is an IMRT process that uses probabilistic (stochastic) dose-volume-based pDVH
objective functions to adjust the beam fluence intensity profiles. Denote Dv the dose delivered to
volume v of an ROI. In contrast to the static Dv in basic criteria/objective functions, COP
computes and optimizes Dv at a specified coverage probability — the probability that a realized
target or OAR dose metric Dv exceeds the dose of interest (Rx, tolerance or other dose) when the
modeled treatment planning and delivery uncertainties are taken into account. COP seeks an
optimized dose distribution for a patient to i.e., maximally achieve targets and OARs coverage
probability to overcome the degraded dosimetric effect due to GUs.
The procedure of COP optimization on the patient-specific coverage probability with
incorporated GUs of known PDFs is graphically illustrated in Figure 6.

The deviations

introduced by GUs may include shifting effects (due to systematic setup errors), blurring effects
(due to random setup errors) and re-arranging dose with respect to the voxels (due to organ
deformation). Different probable treatment courses (one treatment course = delivery of the
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prescription dose in nfrac fractions) can yield different dose distribution and different patient
responses. To evaluate dose incorporating uncertainties, one way is to mimic dose delivery to
one of thousands of possible virtual treatment courses, each with nfrac fractions. Each fraction of
each treatment course is associated with different GUs dependent on the parameters sampled
from the known PDF(s). Dose shift invariance (Sharma et al. 2012) is assumed here so that dose
distribution remains unchanged regardless of geometric changes of ROIs.

Dose of each

displaced voxel in the ROIs is calculated and accumulated over nfrac fractions. The consequent
accumulative DVHs of each ROI for all the treatment courses can be obtained and converted into
a dose volume coverage map (DVCM) – a 2D grid with many small grid squares that contain
percentile values of DVHs on their Dv locations. (See section 3.2.1 for details) These percentile
values, also called coverage probability, are associated each Dv on the DVCM. A pDVH of q
(Gordon et al. 2010) is a virtual DVH created by connecting all Dv with coverage probability q.
A pDVH criterion for q is Dv corresponding to q for a target/an OAR.

Figure 6. Workflow of how a pDVH of coverage probability q are determined (a–c) and how COP performs
optimization (a-d) based on pDVH criteria by simulating ntx virtual treatment courses, each with nfrac
fractions. (a) For each fraction of a virtual treatment course, find the total offset (black arrow) for all the
GUs of each voxel in the ROI (black thick circle) and get the dose for the displaced voxel, assuming shiftinvariance for dose distribution (illustrated as grey thin solid isodose lines). (b) Get ntx accumulative ROI
DVHs over all the fractions. (c) The ntx DVH samples are converted into a dose volume coverage map
(DVCM), as a 2D grid built with many small grid squares. Each grid square will be assigned a probability
value equivalent to the percentile value of DVHs that lie left to this grid squares, according to the
distribution of DVH samples. A virtual DVH of a certain percentile value (i.e., coverage) q, namely pDVH
of q, can be determined on this map. (d) pDVH criteria (such as Pr[Dv ≥d] ≥q) are used to optimize the dose
distribution with the goal of achieving dose-volume metric Dv in the presence of q of GUs.
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Note that the concept of pDVH is not unique. A similar metric called dose–volume
population histogram (DVPH) related to the patient-specific coverage probability was
independently and simultaneously developed before (Nguyen et al. 2009). With known SDs of
the systematic and random errors for deformation-free/rotation-free structures, DVPH was the
consequence of the distribution of systematic and random errors being incorporated into DVH
display. Compared to DVPH, the usage of pDVH in this dissertation has been extended to plan
optimization to account for GUs for both rigid and deformable structures.
2.2 The starting point — optimization criteria
As mentioned before, the planner needs to specify optimization criteria to start an
IMRT/COP plan. The optimization criteria for treatment planning used in this dissertation are
listed in Table IV. Based on a modified VCU protocol, these criteria are designed for a 30fraction treatment course for high-risk prostate cancer patients. ROIs corresponding to these
criteria include target structures to treat and normal tissues/organs to protect. Target structures
for COP plans are the CTV volumes which include the prostate and the seminal vesicles
(namely, CTVprostate and CTVSV).

Their PTV-margin-expanded volumes PTV1, PTV2 are

surrogate target structures used in PTV plans. Normal tissues/organs for both COP and PTV
plans are the bladder, rectum as OARs and norm_tissue_ring which is a virtual structure used to
ensure a steep target dose drop-off. Three types of criteria are involved here. (1) Dose-based
criteria (e.g. Dmax  60 Gy for norm_tissue_ring) specify the minimum or maximum dose to the
whole volume of an ROI. Norm_tissue_ring Dmax  60 Gy means the maximum dose delivered
to the norm_tissue_ring cannot be larger than 60 Gy. (2) Dose-volume-based criteria (e.g., D98 ≥
78 Gy for prostate in PTV plans) that restrict dose to a certain percentage of ROI volume.
CTVprostate D98 ≥ 78 Gy means dose delivered to the 98% volume of the CTVprostate should be
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above 78Gy. (3) pDVH based criteria (e.g., D98,95 ≥ 78 Gy for prostate in COP plans) specify
dose-volume criteria corresponding to a certain coverage probability. Prostate D98, 95 ≥ 78 means
that the dose delivered to the 98% volume of the prostate should be no less than 78 Gy for 95%
probablle treatment courses.
Table III. IMRT optimization criteria of ROIs used for COP and conventional PTV plans. Doses (D) are in
the unit gray (Gy). Subscript is percentage volume +/- coverage value. Read D98,95 as 98% of volume receiving
≥ 78 Gy for 95% of simulated treatment courses. Criterion weights are shown in square brackets. PTV1 =
CTVprostate + PTV margin and PTV2 = CTVSV + PTV margin.
Optimization criteria for COP plans1
CTVprostate

D98, 95 ≥ 78 [100], D2 ,5  81 [50]

CTVSV

D98, 95 ≥ 66 [100]
D70, 5  18, D50, 5  36, D30, 5  57 , D20,5  66 ,

Bladder
D14,5  69, D9,5  75, D2,5  81 [10]
Rectum

D50, 5  36, D30, 5  51, D20, 5  66 , D5, 5  69, D2, 5  75 [10]

norm_tissue_ring

(static) Dmax  60 [1]

CTV_neighborhood

(static) D10 ≥ 25 [0]

Optimization criteria for PTV-based plans
PTV1

D98 ≥ 78 [100], D2  81 [50]

PTV2

D98 ≥ 66 [100]
D70  18, D50  36, D30  57 , D20  66,

Bladder
D14  69, D9  75, D2  81 [10]
Rectum

D50  36, D30  51, D20  66, D5  69, D2  75 [10]

norm_tissue_ring

Dmax  60 [1]

Note, margin formulation (Stroom et al. 1999, van Herk et al. 2000) are designed to dicit a population
based probability (e.g., 95%) of target coverage. As used for optimized margin, the PTV margins are iterated until
95% coverage is achieved.
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Once the optimization criteria are specified, an optimization altorithm is used to
determine beam fluence distribution which best meet the optimization objectives. One broad
category of computer algorithm to do so is called iterative methods (Khan 2003). Such methods
interatively adjust beamlet weights for a given number of beams to minimize the deviation from
the desired goal. Mathematically, this deviation is represented by the sum of objective functions
which are transformed from the specified optimization criteria.
2.3 The central concept — objective functions
Objective functions are the central concept of IMRT inverse planning to generate a dose
distribution that can maximally satisfy the specific optimization criteria. They are also termed
cost functions since they represent the “costs” associated with a dose distribution of a given plan
and a set of pre-determined optimization criteria. Let f denotes an individual objective function
for the objective of interest o , f can also be expressed in a generalized way as
N

f   ci (Di  DRx )2

(1)

i

where Di is the current dose to i th voxel of o , DRx is the prescribed dose to be achieved for this
objective, N is the total number of voxels and ci is a voxel-dependent constant. ci is zero when
the voxel is not participating in the objective function.
With the aims of reducing total “cost” of all the individual objective functions, the dose
distribution is iteratively optimized by adjusting treatment parameters (i.e., beamlet weight) to
decrease composite objective function value.

Let ftotal ,n denote the total objective in n th

iteration of optimization. We have
nObj

ftotal , n   p  f n
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(2)

where f n is an individual objective function for the objective of interest o in n th iteration. p is
weighting factor of f n and nObj is the total number of objectives of interest.

ftotal ,n is

transformed according to the TPS algorithm and then compared with a pre-defined stopping
tolerance (e.g., 0.0001) to determine if next iteration of optimization is necessary.

The

optimization terminates whenever the stopping tolerance has been satisfied or n exceeds the
maximum iteration number (e.g., set as 50 here due to sufficient convergence).
Within the TPS optimizer, dose optimization by adjusting beamlet weight for next
iteration is carried out by utilizing Newton’s method. Denote beamlet weight w j ,n for beamlet
index j is the index of beamlet in n th iteration. The recommended change in weight  w j ,n1 in
next iteration for an individual objective function f n is defined as

 w j , n 1  

f n
w j , n
2 fn
w j , n 2

(3)

based on Newton’s method. Since the dose at voxel i is given by
Di   K ij w j

(4)

j

where K ij is the dose contribution of the j th beamlet to the i th voxel per unit intensity, the first
derivative of equation (1) is
N
f n
 2 ci (Di  DRx ) Kij
w j ,n
i

(5)

and the second derivative of equation (1) is

N
2 fn

2
i ci Kij 2
w j , n 2
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(6)

For a composite objective function in equation (2), the derivatives are the sums of the individual
derivative of each objective function:
ftotal ,n
w j ,n

nObj



 2 ftotal , n nObj  2 f n
f n
and

w j ,n
w j ,n 2
w j ,n 2

(7)

According to equations (3)-(7), the weight change for a given beamlet is then

 N

  2i ci (Di  DRx ) Kij 
 w j ,n 1  
nObj
 N

  2i ci Kij 2 
nObj

(8)

The new beamlet weight for n  1 th iteration is
w j ,n1  wj ,n  wj ,n 1

(9)

An example of how a composite objective value converges during the progress of an
optimization is illustrated in Figure 7. The optimization is terminated in either of the following
conditions: i) constraints and objectives are reasonably met as to the pre-defined stopping
tolerance, ii) the maximum iteration number is reached, or iii) further iteration is determined as
helpless to keep reducing the composite objective value.

(a)

(b)

Figure 7. The converged composite objective value (vertical axis) as a function of iterations during the
progress of optimization in the case that optimization terminates (a) when constraints and objectives
are reasonably met as to the stopping tolerance and (b) when further iteration is determined as
helpless.
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2.4 Types of objective functions
Three types of objective functions will be described here in term of the three types of
optimization mentioned in Table III: 1) dose based objectives for dose-based criteria, 2) dosevolume based objectives for dose-volume-based criteria and 3) pDVH objective, which is the
research objectives used to achieve the aims of this dissertation. The pDVH objectives are
particularly used in COP to achieve pDVH criteria. 1) and 2) are the basic format of objectives
that operate on static DVH and are used in both conventional non-probabilistic optimization and
COP. These basic objectives are useful for COP as they can (i) smooth the dose around target in
the first several (~5) iterations for quicker convergence of composite objective value and (ii)
save computation time and memory for COP implementation when an ROI that is not that
critical to have pDVH objectives.
2.4.1

Dose-based objectives

Dose-based objective functions primarily build blocks for the desired DVH by penalizing
dose above (or below) a specified dose to an ROI. (Here, DVH is a graphical 2D plot of dose vs.
percentage volume for an ROI visualized in a cumulative way. Please refer to section 3.1 of
chapter 3 for more details.)

The corresponding criteria can be written in the form of

Dmax  DRx (maximum), Dmin  DRx (minimum) or Duniform =DRx (uniform), where DRx is the
corresponding maximum, minimum or uniform prescription dose value.
For a minimum dose-based objective function of an ROI (with criterion Dmin  DRx ), the
goal is to ensure the dose to each voxel is above a minimum prescription dose DRx . The voxels
within the ROI with dose below the prescription dose are penalized proportional to the deficit
squared as
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f MinDose 

1 N ROI
  H (DRx  Di )  (Di  DRx ) 2
N ROI i

(10)

where i is the voxel index of total voxel number N ROI of ROI, Di is the dose in the i th voxel of
the ROI and H is Heaviside function defined as
1
H ( x)  
0

( x  0)
( x  0)

(11)

Note, voxels outside ROI do not contribute to the ROI objective function.
For a maximum dose-based objective function of an ROI (with criterion Dmax  DRx ), the
goal is to limit the dose to each voxel below a maximum prescription dose DRx . The voxels
within the ROI with dose above the prescription dose are penalized proportional to the excess
squared as
f MaxDose 

1 NROI
  H (Di  DRx )  (Di  DRx ) 2
N ROI i

(12)

For a uniform dose-based objective function of an ROI (with criterion Duniform  DRx ), the
goal is to make the dose to each voxel equivalent to a uniform prescription dose DRx . The
voxels within the ROI with dose above or below the prescription dose are penalized proportional
to the deviation from the uniform dose squared.

This is equivalent to a combination of

maximum and minimum dose-based objectives.
f Uniform 

1 N ROI
  (Di  DRx )2  f MaxDose  f MinDose
N ROI i

(13)

Details of dose-based objective functions are described by Wu and Mohan (Wu and Mohan
2000).
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2.4.2

Dose-volume based objectives

Dose-volume based objectives corresponds a dose-volume based criterion in the form of
DvRx  DRx (maximum) or DvRx  DRx (minimum), where DvRx is the dose computed to the

prescription volume v Rx of objective’s ROI for a given dose distribution. Here, dose received by
a proportion of voxels is constrained to be above or below a prescription dose DRx . (Note that
dose-based objectives are special cases of dose-volume based objectives when v Rx = 100% for
maximum or v Rx = 0% for minimum objectives.) Figure 8 shows an example of how a minimum
and a maximum DVH objectives work on a DVH graphically. During optimization, DvRx is
recomputed for each iteration after beamlet weight for each beam has been adjusted according to
equation (9) .

Figure 8. Graphical illustration of variables for (left) a minimum DVH objective (with goal Dv  DRx ) and
Rx

a maximum DVH objective (with goal Dv  DRx ) The blue curve and the black curve represent desired
Rx

DVH and current DVH. D v

Rx

and DRx are the current and prescription dose to the prescription volume

v Rx . The purpose of this DVH objective is to have the DVH ( D v , v Rx ) optimized to the desirable location
Rx

( D Rx , v Rx ). The red shaded region is the penalty region.

For a minimum DVH objective (with criterion DvRx  DRx ), the goal is to keep the dose
to the percentage of voxels (≤ the prescription volume v Rx ) above the prescription dose DRx .
Only those voxels with dose between DvRx and DRx are penalized. (See the pink region in
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Figure 8.) The voxels with higher dose than DRx have no penalty because they meet the
constraints of the objective. The voxels with lower dose than DvRx have no penalty because they
are in the permitted percentage of the high dose volume, i.e., Dvtotal -vRx  DRx is allowed with
respect to DvRx  DRx where v total is the total percentage volume of ROI. The objective function
is
f MinDVH 

1 NROI
  H (DRx  Di )  H (Di  DVRx )  (Di  DRx ) 2
N ROI i

(14)

When D v is optimized above DRx , the function value is 0 as the objective has been fully
Rx

satisfied.
For a maximum DVH objective (with criterion DvRx  DRx ), the goal is to limit the dose
to the specified percentage of voxels (≥ the prescription volume v Rx ) to be below the
prescription dose. Analogous to the minimum DVH objective, only the voxels with dose below
DRx and above DvRx are penalized. The objective function of the maximum DVH objective can

be
f

MaxDVH

1 NROI

  H (Di  DRx )  H (DVRx  Di )  (Di  DRx ) 2
N ROI i

(15)

When DvRx is optimized below DRx , the function value is 0 as the objective has been fully
satisfied. Details of dose-volume-based objective functions are described by Wu and Mohan
(Wu and Mohan 2000).
2.4.3

pDVH based objective

The pDVH objective functions (Gordon et al. 2010) serve as key functions for COP
optimization. As mentioned before, pDVH is a result of “dynamic” DVHs which are different in
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each virtual treatment course due to the different GUs sampled from PDFs of GU model. Unlike
the previous basic objectives that operate on static DVH, pDVH-based objectives operate on
pDVH with GU variability considered. These objective functions are utilized in COP to meet
pDVH criteria in the format of Pr[DCRx  DRx ]  qRx (minimum pDVH criteria) or

Pr[DCRx  DRx ]  1  q Rx (maximum pDVH criteria) or where DCRx is dose at prescribed coverage
and Pr[] denotes the probability of a DVH-based objective ( DCRx  DRx or DCRx  DRx ) is met
and q Rx is the prescribed coverage probability value. A typical value of q Rx is 95% for target
volumes and 5% for OAR to allow 5% outlier cases.

Figure 9 shows an example of how

maximum pDVH objective works on a pDVH graphically. During optimization, DCRx must be
recomputed in each iteration.

Figure 9. Graphical illustration of variables for a minimum pDVH objective (left) and a maximum pDVH
objective (right) in the form of Pr[DC  DRx ]  q Rx and Pr[DC  DRx ]  1  q Rx . The blue curve and the
Rx

Rx

black curve represent desired pDVH and current pDVH of coverage value q Rx . DCRx and DRx are the
current and prescription dose to the prescription volume v Rx . The purpose of this pDVH objective is to
pull the pDVH from ( DCRx , v Rx ) to the desirable location ( DRx , v Rx ) on the pDVH plot.

For a minimum pDVH objective (with criterion Pr[DCRx  DRx ]  qRx ), the goal is to
ensure that dose at the prescribed coverage q Rx , DCRx , achieves the prescription dose DRx . The
objective function is written as
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f

MinpDVH



1
N ROI _ neighborhood



N ROI _ neighborhood


i

H (DRx  Di )  H (Di  DCRx )  i 2 (Di  DRx ) 2

(16)

where ROI _ neighborhood refers to the voxels within an ROI neighborhood composed of ROI
and a ring structure surrounding the ROI, and i stands for a voxel-specific weighting factor.
Only voxels within ROI _ neighborhood with Di between DCRx and DRx are penalized.
For a maximum pDVH objective (with criterion Pr[DCRx  DRx ]  1  q Rx ), the goal is to
ensure that dose at the prescribed coverage q Rx , DCRx , is below the prescription dose DRx for at
least 1- q Rx chance. The objective function is
f MaxpDVH 

1
N ROI _ neighborhood



N ROI _ neighborhood


i

H (Di  DRx )  H (DCRx  Di )  i 2 (Di  D Rx ) 2

(17)

When DCRx is optimized below DRx , the function value is 0 as the objective has been fully
satisfied.
The novelty of using ROI _ neighborhood and voxel-specific weight i makes COP
distinctive from other treatment planning techniques. ROI _ neighborhood is a PTV-like structure
to include all the voxels that potentially contribute the ROI coverage, and i is to weight each
voxel inside ROI _ neighborhood based on its contribution of ROI converge. As opposed to that
a PTV is determined empirically and assumed of equal importance for each voxel, both
ROI _ neighborhood and i are determined by simulating GUs in a large number of (e.g., 1000)

virtual treatment courses before optimization starts. To make sure ROI _ neighborhood is large
enough, ROI is first expanded by 1 voxel to include the nearest exterior surface voxels for the
purpose of dose interpolation. Then possible voxel locations as a result of ROI offset in the
virtual treatment courses are added to this ROI _ neighborhood .
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Let ROI _ ring denote a

concentric series of ROI _ neighborhood voxels which exclude ROI voxels. Since its location
and chance of being covered by the “moving” ROI are different from others, each ROI _ ring
voxels may have different contributions to ROI coverage probability. To consider this, i is
used to weight the squared dose term in equation (17) for each ROI _ neighborhood voxel. i
can be expressed as an empirical function below

5

4

1
 1  5     d  


v n  ROI
vn  ROI _ ring = ROI _ neighborhood - ROI

(18)

The empirical weight is constantly 5 for ROI voxels and ranges from 1 to 5 for ROI _ ring
voxels. To weight a ROI _ ring voxel, a quantity  is used to represents a “voxel distance” in
the form of

  norminv  probROI , 0, 0.3

(19)

where probROI is probability that a ROI _ ring voxel may be covered by the “moving” ROI due
to GUs, norminv() is the normal inverse cumulative distribution function with parameters

probROI as probability, 0 as mean, 0.3 as SD.  decreases from  to 0 as probROI increases
from 0 to 1. If a ROI _ ring voxel dose is d ,   d  represents the minimum  value among all
the ROI _ ring voxels whose dose are d . The smaller     d  is, the larger  (and more
important coverage contribution) of the ROI _ ring voxel is.

The mechanism of i is to

encourage the optimizer to optimize dose to ROI voxels first and then ROI _ ring voxel from
“near” (=more important) to “far” (=less important).

Thus, more rapid convergence of

optimization can be achieved to shape a desired dose distribution.
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2.5 Implementation of objective functions in a commercial TPS
A base theoretical method of IMRT and COP optimization has been described in the
previous sections. The commercial TPS in this dissertation is Pinnacle3 9.0 (research version)
(Philips Healthcare, Andover, MA). To implement COP to Pinnacle3, practical modifications are
required including (1) a change in the format of objective functions, (2) beam fluence
initialization for the pDVH objectives used in COP.
2.5.1

Reformatted objective functions

All the objective functions mentioned before are reformatted when used in Pinnacle3.
The ROI volumes are normalized to 1, so the

1
term is not necessary in the objective
N ROI

functions. Additionally, the weighting factor p in equation (2) is moved into each individual
objective function. For example, a maximum DVH objective in equation (15) becomes
f MaxDVH 

N ROI

 p V  H (D
i

i

i

 DRx )  H (D vRx  Di )  (Di  D Rx ) 2

(20)

where is Vi the normalized volume of each voxel.
2

 1 
 to normalize scores from different prescription dose
 DRx 

Also, a scaling factor SPinn  

levels is used to eliminate the dose-dependent term in derivatives. In this way, the example
objective in equation (20) is changed to
F MaxDVH 

N ROI

 p V  S
i

i

Pinn

 H (Di  DRx )  H (DvRx  Di )  (Di  DRx ) 2

(21)

where F denotes the Pinnacle3 objective function for a objective of interest o .

The first

derivative and the second derivative of the non-zero part of equation (21) with respect to the
beamlet weight w j are
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N ROI
F MaxDVH NROI
  2  p  Vi  SPinn  H (Di  DRx )  H (DvRx  Di )  (Di  DRx )  Kij   Gi MaxDVH  Kij
w j
i
i

(22)

and
N ROI
 2 F MaxDVH NROI
2

2

p

V

S

H
(D

D
)

H
(D

D
)

K


i H i MaxDVH Kij 2
i
Pinn
i
Rx
vRx
i
ij
w j 2
i

(23)

Particularly, Gi MaxDVH in equation (22) is the Pinnacle objective function gradient on a per voxel
basis.

Gi MaxDVH is used since Pinnacle computes and stores K ij independently of the first

derivative matrix. The separation results in K ij being dependent only on the beam and anatomy
configuration and independent of objective function. For a similar reason, H i MaxDVH is used in
equation (23). It is a constant handled internally in Pinnacle3.
To sum up, as IMRT inverse planning is a process of iteratively computing the composite
nObj

cost function and changing beamlet weight, Pinnacle3 computes function value Ftotal   F and
nObj

the gradient Gtotal ,i   Gi to adjust beamlet intensity via Newton’s method for each iteration.

2.5.2

Beam fluence initialization for COP

Readers may have already noticed that in Table III (page 22) a structure called
CTV_neighborhood is added to the optimization criteria for COP plans. CTV_neighborhood is a
virtual target expansion utilized as an initial target volume in Pinnacle3. The initial target
volume forces Pinnacle3 to set initial beamlet intensities, in order to permit creation of a desirable
dose distribution. This volume may be not necessary in other TPS but required to be determined
before COP optimization in Pinnacle3. At the start of an optimization, Pinnacle3 initializes
beamlet intensities to a nonzero value only for those beamlets that traverse the initial target
volume. The intensities of all other beamlets are initialized to zero, and remain zero through the
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optimization. For conventional PTV-based plans, the initial target volume is not required since
PTV using minimum dose-based or dose-volume based criterion is regarded as the default initial
target volume. However, for COP plans, the target structures CTVprostate and CTVSV are too
small to be used as the initial target volume. GUs can result in CTVprostate or CTVSV occupying
voxels outside its static contoured boundary (in the accelerator coordinate system). Dose in
these “exterior” voxels affects coverage probabilities of CTVprostate and CTVSV, too. To ensure
enough voxels are occupied, the CTV_neighborhood is used in COP as the initial target volume.
In this dissertation, CTV_neighborhood is empirically defined as the union volume of CTVprostate
and CTVSV on all fractions of patient database (see chapter 4.1) with a uniform expansion by 12
mm.
2.6 Summary
COP is a modified inverse planning technique of IMRT process, where beam
fluence/intensity is adjusted in the goal of minimizing the composite objective function
associated with the optimization criteria. The novelty of COP is using pDVH criteria and pDVH
objectives to seek an optimized dose distribution to i.e., maximally achieve targets and OARs
coverage probability at prescribed value to overcome the degraded dosimetric effect caused by
GUs. In the pDVH objective functions, some exterior ROI voxels with potential contribution to
ROI coverage probability are particularly included and weighted according to their potential
contribution. To implement COP in a commercial TPS Pinnacle3, the objective functions need to
be reformatted and beam fluence initialization is required.
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3

Metrics for plan evaluation

In clinical radiation therapy plan development, plan evaluation serves to judge one or
inter-compare two competing treatment plans with respect to the treatment objectives. Planning
metrics distill information contained in a complex patient 3D dose distribution into quantities
that can be readily compared. These metrics/quantities are very useful to help determine whether
COP is needed to optimize a current dose distribution and how better or worse COP plans can be
relative to other PTV plans.
This chapter examines planning metrics for plan evaluation, optimization and
comparison.

Some are dosimetric endpoint metrics and the others are biological endpoint

metrics. These metrics are used in the following chapters to investigate the potential clinical
impacts of GUs and the planning methods (including COP) used to compensate these clinical
impacts.
3.1 Dosimetric endpoint: dose-volume metrics
In clinical practice, dose-volume metrics of a specified structure are most commonly and
routinely used metrics for plan prescription and reporting. These metrics conveniently reveal the
relationship of the absorbed dose to relevant anatomic volumes. For example in Table IV, Dv
represents absorbed dose to v% volume of the structure. For a target structure, Dmin (= D100) or
D98 is often used to quantify the minimum dose to be delivered. D98 is used instead of Dmin when
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2% volume cold spot4 is allowed. A typical dose-volume metric based criterion/prescription can
be D98 ≥ d.
Dose metrics can be read by a calculating associated dose volume histogram (DVH)
which is composed of all the dose-volume metric points. A DVH summarizes a 3D dose
distribution (which is a 3D dose array computed for all voxels) of a structure in a graphical 2D
format. A DVH is usually visualized in a cumulative way. A cumulative DVH displays the
percentage of the volume of a given region of interest which receives greater than a specified
dose.

Note in this dissertation, DVH elsewhere refers to cumulative DVH.

Figure 10(a)

demonstrates how a DVH can be used in plan comparison. DVH A lies to the right of DVH B.
The dose received by a certain percentage volume of an ROI in DVH A is always higher than
that in DVH B. If DVH A and DVH B are both for the same ROI, DVH A is usually preferred
when the ROI is a target structure to achieve high and uniform prescribed dose. Otherwise,
DVH B is better as low dose to an OAR is desired.
Table IV. Dose-volume metrics that can be obtained from a DVH curve

Metric
Dv

Meaning
Absorbed dose to v% volume of the structure.
e.g.,
Davg =Average dose
D50 = Median dose
D98 = Near minimum dose
D2 = Near maximum dose

VD

volume receiving at least an absorbed dose of D

4

A cold spot refers to an area in the target that receives a lower dose than the specified target dose. Only if
its area covers at least 2 cm2, a cold spot is considered clinically meaningful. (Khan 2003)
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(b)

(a)

Figure 10. Two examples of (a) a simple (cumulative) DVH comparison and (b) a complex DVH
comparison between A and B. Example (b) is complex because two DVHs of same ROI can have same
(i.e., min, average and max) dose metrics.

However, DVH has limitations. First, the standard DVH loses spatial information of
dose distribution. It is impossible to locate a specific position of an ROI voxel on a DVH in
Figure 10. To augment this, many methods have been proposed i.e., to show distance between
ROI voxels in DVH to either the ROI or another adjacent ROI. (Cheng and Das 1999, Chao et al.
2003, Bortfeld et al. 2008, Wu et al. 2008, 2009, 2011, Huang et al. 2010, Zhao et al. 2010, Zhu
et al. 2011, Witte et al. 2011, Mayo et al. 2013) One example is to calculate vectors pointing
from the voxels in one ROI DVH to the nearest points on surfaces of other ROI and add the
vector information on a DVH. (Mayo et al. 2013) However, these methods are still proof-ofconcept and cannot totally represent 3D dose distribution. They are so far only used in-house by
the developers and have not been standardized.

Another limitation of DVH is that DVH

comparison can be very complex sometimes. It is possible that two DVHs from competing plans
cross on another and may share the same average/min/max dose (e.g., Figure 10 (b)). Therefore,
a thorough review of the 3D dose distribution or other metrics is still needed to judge or compare
treatment plans.
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3.2 Dosimetric endpoint: coverage probability
Coverage probability is an important and unique dosimetric concept that directly reveals
the relationship of ROI dose and GUs. This metric is important for the evaluation/comparison of
plans under the influence of GUs. A coverage probability value is the probability that a realized
target or OAR dose metric Dv exceeds the dose of interest (Rx, tolerance or other dose) when
treatment planning and delivery uncertainties are taken into account. (Gordon and Siebers 2008)
For evaluation of a static plan (one free of GUs), coverage probability reduces to boolean (i.e.,
0% or 100%) values. However, realistically, a static patient geometry is not possible in multifractioned radiation therapy. Coverage probability values of targets and OARs often differ
considerably from the value implied by the static plans (Gordon and Siebers 2008, Xu et al.
2011). Therefore, coverage probability evaluations are essential for evaluating plans under the
influence of GUs.
Two methods have been used to estimate coverage probability. One is using DVCM and
the other is dosimetric margin distribution (DMD). The DVCM method estimates coverage
probability by simulating possible treatment outcome while the DMD method calculates
coverage probability by a formula under the condition that the relationship of GUs PDF and
coverage probability is known. In fact, the DMD method is a simplified version of the DVCM
method when a simple GUs PDF (e.g., Gaussian) is considered. Compared to the DMD method
which estimates coverage probability values for only a single dose-volume metric, the DVCM
method (mentioned in section 2.1) is more general and permits simultaneous analysis of multiple
dose-volume metrics. Therefore, the DVCM method is used to estimate coverage probabilities
for this dissertation. Both methods will be discussed in the following paragraphs.
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3.2.1

Coverage probability estimation method: DVCM

One way to estimate coverage probability is by constructing a DVCM, a 2D dose volume
coverage map that contains coverage probability for each dose-volume metric for an ROI.
(Gordon et al. 2010) It has been mentioned briefly in the workflow of pDVH and COP in Figure
6 (page 20) and will be described in detail (Figure 11) here. To get a DVCM, a large number
(ntx) of virtual treatment courses, each with multiple fractions (nfrac) are simulated. For each
virtual treatment course, different GUs sampled from PDF of the constructed GU model result in
different ROI DVHs as a result of the accumulated dose distribution of all the nfrac fractions. The
axes of dose and volume of DVH are divided into small increment, 0.1Gy and 1% respectively,
to create a 2D grid map. For the 1st DVH of the 1st virtual treatment course, the grid squares
below or left to the DVH curve are assigned value 1.0 (=100%) and the others are 0.0. Then for
each DVH, increment all grid squares lying below or to the left of the DVH by 1.0. All the grid
values are divided by total number of DVHs (=ntx) to finalize this map, which is so-called
DVCM. In an ROI DVCM, each grid square (corresponding dose d and volume v) contains the
probability that, in an individual treatment course, Dv ≥ d can be achieved for the ROI when
GU(s) are considered. For the example of a ROI DVCM in Figure 11, Dv with probability 1.0
can be achieved 100% based on the 2 simulated virtual treatment courses. The probability of
each grid square is called the coverage probability corresponding to the metric Dv and can be
used for plan evaluation and/or optimization.
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Figure 11. Example of how a ROI DVCM is generated for a simple case with only two virtual treatment
courses. Get DVH (grey lines) with different GU(s) for each treatment course. For each DVH, increment
all grid squares lying below or to the left of the DVH by 1.0. Then normalize the whole grid values.

3.2.2

Coverage probability estimation method: DMD

Another way to estimate coverage probability is via a DMD, the distribution of
dosimetric margins (DMs) over 3D directions. DMD was inspired by the fact that ROI coverage
probability with respect to dose d is a function of the distance between the ROI and the volume
enclosed by the critical isodose surface of dose d. (Gordon and Siebers 2008) Such distance in a
specific direction (φ, θ) is called DM and denoted as Mv,d(φ, θ). DM is the safety margin that the
ROI can be offset while still satisfying a dose constraints Dv ≥ d for CTV or Dv ≤ d for OAR.
For example Mmin,70(φ, θ) (=M100,70(φ, θ)) denotes the maximum distance the CTV (or OAR) can
be offset in the direction (φ, θ) before its Dmin (=D100) falls below (exceeds) 70 Gy. For an
isodose surface that is within or crosses the structure, DM = 0. Examples of DMD for a target
CTV and a bladder for prostate cancer treatment are shown in Figure 12. A type I (type II) ROI
indicates that the static plan meets (violates) the specified dose-volume criteria. A type II ROI is
non-standard and ends up with low coverage for targets and high coverage for OARs. Please
refer to Appendix II.b for detailed distinction of type I and type II structures.
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Figure 12. Examples of DMD sampled using fixed angular increment method for (a) CTV D min, 79.2(type I),
(b) bladder D25, 70 (type I) and (d) bladder D25, 70 (type II) (Xu et al. 2011)

When DM M v,d ( , ) and geometric uncertainty parameter(s) such as SD of systematic
setup errors Σ are known, the corresponding coverage probability Q( , , ) in this specific
direction can be estimated using the following function,
Q( , , )  f (M v,d ( , ), )

(24)

where f() denotes a coverage function whose form depends on the PDF of the geometric
uncertainty. Note here we use Q (not q ) to represent the coverage probability that is obtained
via DMD method (not DVCM method). The overall coverage Q() is
Q()  W ,  Q( , , )
 ,

(25)

where W , is a weighting factor equal to the fraction of 4π sr covered by the ray in the direction
(φ, θ). An example of how Q() of a CTV and an OAR varies with Σ is shown in Figure 13,
where random uncertainties are accounted for through fluence convolution. Each coverage curve
corresponds to a single dose-volume metric Dv of the ROI.
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Figure 13. Qualitative dependence of coverage probability Q on systematic SD for type I targets and type
I/II OAR. (Xu et al. 2011)

For coverage estimations using DMD method, it is important to note that a sufficient
sample of DM is required to ensure a representative DMD and accurate Q . The earlier study
(Xu et al. 2011) proved that DMD sampling with angular increment ω (fixed angular increment
method) or ωeff (isotropic sampling method) = 10° and δ = 0.5 mm should be adequate for
planning purposes.
3.3 Biological endpoints: BED, EUD, TCP and NTCP
Biological metrics in this dissertation refers to metrics that are modeled to correlate
physical dose to biological response such as cell killing and normal tissue complication. The
biological metrics related to this dissertation include biological equivalent dose (BED),
equivalent uniform dose (EUD), tumor control probability (TCP) and normal tissue complication
probability (NTCP). Biological models used in biological metrics intend to represent complex
reality (i.e., clinical observations of cell radiobiology response) by simplistic equations and a few
parameters.

Such models, if realistic and representative, could be considerably useful in both

plan evaluation and optimization. However, uncertainty introduced by the models and their
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parameters associated with the biological metrics remains a concern. (ICRU Report 83 2011)
After all, the complex biology of tumors and normal tissues for each patient is unlikely to be
represented by a single equation with population-based parameters. Therefore, ICRU 83 report
suggests using biological metrics for secondary plan evaluation only. (ICRU Report 83 2011)
Nonetheless, these metrics provide additional quantitative measures for plan comparisons.
3.3.1

Basic radiobiology: cell survival curves and fractionated dose

The biological effects of radiation lead to a certain level of DNA damage and therefore
cell death in tumors and normal tissues. Damage is tissue-specific and dependent on irradiated
dose and cell characteristics such as sensing and repair of damaged DNA. The cell survival
curve depicts cell survival after irradiation as a function of dose, as shown in Figure 14. The
linear-quadratic model is the most widely accepted way to describe the relationship of cell
surviving fraction S and dose D as.
S  exp( D   D2 )

(26)

where  and  are linear and quadratic component slope when equation (26) is plotted on the
logarithmic scale.   is an important term which shows the tissue sensitivity to dose. When
D =   , linear killing and quadratic killing are equivalent.
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Figure 14. Illustration of (upper) cell survival curve of dose D versus survival fraction S when the  
ratio = 3 and (lower) example of different cell survival curve of early and late response tissues.

Fractionated radiotherapy is performed in clinical treatment to take advantage of
different   ratios between tumors and normal tissues.

As Figure 14 illustrates, late-

responding tissues (lower   ) are relatively more resistant to low doses (=higher survival) and
more sensitive to high doses than early-responding tissues (higher   ). There is a growing
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consensus that   for prostate cancer is lower than that of normal tissues. (Fowler et al. 2001,
Bentzen and Ritter 2005, Daşu 2007, Fatyga et al. 2009) If this is true, theoretically, increasing
the dose per fraction (and therefore larger fraction size) can result in more injury (or less repair)
to the prostate cancer cells than surrounding normal tissues.
To consider   and fractionation scheme with respect to biological response, BED is
often computed. Based on the linear quadratic model, BEDi of fraction i with dose Di is
 D /n 
BEDi  Di  1  i

    

(27)

where n is the total number of treatment fractions and   is the tissue-specific fractionation
sensitivity.   introduces uncertainties of BED estimation as its value is still debated. Here, a
relatively conservative   = 3 is selected for prostate (Fatyga et al. 2009).   = 5 is
assumed for bladder and rectum.
3.3.2

Equivalent uniform dose

EUD of an ROI is the uniform dose that would give the same biological response as the
non-uniform dose distribution of interest. EUD was originally introduced in a mechanistic
model for tumors by employing the linear quadratic cell survival formalism. (Niemierko 1997)
Later, generalized EUD (gEUD) was presented to make the concept of EUD applicable to both
tumours and normal tissues (Niemierko 1999). gEUD replaces a complicated dose distribution
by a single scalar dose value. This value is calculated based on the assumption that all the other
conditions (e.g., patient, dose fraction, total dose) of the non-uniform dose remain unchanged.
The equation of gEUD is
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1/ a



gEUD  n   νi  Dia 
 i


(28)

where n is the total number of treatment fractions, ν i is the volume of the dose–volume bin with
absorbed dose Di , and the exponent a is a response-specific parameter. For tumor control in
target structures (e,g., prostate), a < 1 so that gEUD is more sensitive to the lower doses. For a
(parallel-like) normal tissue such as lung, a = 1 and gEUD is equivalent to the mean dose. For a
(serial-like) normal tissue, a > 1 so that gEUD is largely affected by the higher dose. a may be
determined empirically by fitting dose-volume data, but there are no universal recommendations
value for a . Here a = 0.16 (Fatyga et al. 2009), 20 (Cahlon et al. 2008), 11.1 (QUANTEC) are
used for prostate, bladder and rectum, respectively.
As an extension of concept of gEUD, general equivalent uniform biological effective
dose gBEUD can be calculated by substituting Di by biological effective dose BEDi (in
equation (27)). Namely,
1/ a



gBEUD    νi  BEDia 
 i


(29)

Both gEUD and gBEUD can be used as an independent metric or a parameter to estimate
another biological metric such as normal tissue complication probability (in section 3.3.4).
3.3.3

Tumor control probability

TCP is a biological metric to predict the probability of long-term recurrence-free survival
(which means the absence of a detectable or symptomatic tumor). The key assumption of all the
TCP models is that a tumor is controlled when all the cells lose clonogenic viability. A TCP
model based on Poisson statistics (Nahum and Tait 1992, Niemierko and Goitein 1993, Webb
and Nahum 1993, Sanchez-Nieto and Nahum 1999) is used in this dissertation. This model
47

simply assumes that all clonogens within the tumor are uniformly distributed and have identical
radio-sensitivities. TCP is estimated from a 3-D dose distribution (with uniform dose Di for ith
voxel) of the tumor (CTV) of total N voxels given the dose required for a 50% probability of
tumor control ( D50 ) and the normalized slope (  50 ) of the sigmoid-shaped dose–response curve
at D50 . The formula is

 ln 2
  
D  
exp  2 50 1  i   
exp  



 ln 2  D50   

 N i
TCP  

  50  gEUD   

1 
 
exp   ln 2  exp  2
ln
2
D50   







non-EUD Possion
(30)

EUD Possion

Parameters for TCP calculations can be obtained from studies that evaluate clinical data for
dose–response relationships. The fitting parameters in (Cheung et al. 2005) are used here. Note
Di (or gEUD) does not have to be physical dose. It can be the BED in equation (29) as long as
D50 is the same type of dose. In this dissertation, BED and gBEUD are used.

3.3.4

Normal tissue complication probability

NTCP is a biological metric used to predict the probability of an OAR complication, such
as bladder bleeding or rectal bleeding that may occur after prostate cancer treatment. The
complication is modeled as a function of the dose (or biological equivalent dose) and volume.
The classic phenomenological Lyman-Kutcher-Burman (LKB) model (Lyman 1985,
Cheung et al. 2005) is most commonly used to calculate NTCP. This model assumes that the
complication probability sigmoid curve can be described by the error function. It explicitly
relates partial-volume tolerance dose through a power law in volume. LKB model can be written
as
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NTCP 

1
2

t

 du exp  u

2

/ 2



(31)

where
t  (gBEUD  TD50 ) / (m  TD50 )

(32)

where gBEUD is general equivalent uniform biological effective dose in equation (29), TD50 is
the tolerance dose producing a 50% complication probability and m is the slope parameter of the
complication sigmoid curve.

Many published values of TD50 and m are inconsistent.

Quantitative Analysis of Normal Tissue Effects in the Clinic (QUANTEC) has recommendations
for the rectum but not for the bladder risk assessment, probably related to the fact that bladder
wall is rarely contoured. Here, bladder parameters are obtained from other literature. (Burman et
al. 1991, Luxton et al. 2004)
The TCP and NTCP models and associated parameters used in the COP studies described
in chapter 5 and 6 are summarized in Table V.

Note the conventional way to estimate

TCP/NTCP of a CTV/OAR after treatment (under the influence of GUs) is via applying the
Table V to the surrogate volumes PTV or PRV. This is based on the assumption that PTV/PRV
exactly represents CTV/OAR with GUs, which is not true in reality. A novel way to incorporate
GUs into TCP/NTCP estimation is by calculating the distribution of the CTV TCP values or the
OAR NTCP values in a large number of virtual treatment courses. The possible TCP/NTCP
distribution reveals the biological effect of GUs to CTV/OAR in a more representative way. An
example of comparing TCP/NTCP distributions of two competing plan is in Figure 18. (chapter
4, page 59)
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Table V. A summary of TCP and NTCP model and parameters for prostate, bladder and rectum used in this
dissertation. Note conventionally TCP or NTCP value is calculated for a PTV or PRV volume. Here, TCP or
NTCP distribution for a CTV or OAR volume is a novel way to account for GUs

TCP: Poisson Model
 ln 2
   BEDi
TCP  exp  
exp  2 50 1 

 N i
D50
 ln 2 


Equation

 
   or
  


   gBEUD   
= exp   ln 2  exp  2 50 1 
 

D50   
 ln 2 

1/ a


D /n

a 
where BEDi  Di  1  i
 and gBEUD    ν i  BEDi 
    
 i


Parameters
Prostate

D50 (dose producing 50% tumor control),  50 (slope parameter),

a (EUD parameter),   (BED parameter)

D50 = 67.5 Gy,  50 = 2.2 , a = 0.16,   = 3Gy

NTCP: Lyman-Kutcher-Burman model

Equation

1

t

2
 du exp  u / 2 
2 
where t = (gBEUD  TD50 ) / (m TD50 ),

NTCP 

1/ a

 D /n


gBEUD    ν i  BEDia  and BEDi  Di  1  i

    
 i


Parameters

TD50 (the tolerance dose producing a 50% complication probability),
m (slope parameter), a (gBEUD parameter),   (BED parameter)

Bladder

TD50 = 80 Gy, m = 0.11, a = 20,   = 5Gy

Rectum

TD50 = 76.9 Gy, m = 0.13, a = 11.1,   = 5Gy

3.4 Summary
This chapter described the dosimetric and biological endpoint metrics used in this
dissertation for plan evaluation, optimization and comparison. The pros and cons of each metric
in terms of its representativeness for plan evaluation are summarized in Table VI. In the
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following COP studies, multiple metrics are calculated to perform a comprehensive plan
evaluation/comparison.
Table VI. Summary of metrics for plan evaluation used in this dissertation. All have the con that 3D
information is lost.
Metric Name

Metric type

Pros

Cons

Dv (DVH)

Dosimetric

simple

Coverage
probability

Dosimetric

GUs incorporated

gEUD(gBEUD)

Biological

TCP (single
value for PTV)

Biological

NTCP (single
value for PRV)

Biological

TCP (distribution
for CTV)

Biological

NTCP
(distribution for
OAR)

Biological

One simple value
substituted from dose
distribution
Treatment outcome
(tumor control rate)
correlated
Treatment outcome
(normal tissue complication)
correlated
Treatment outcome
(tumor control rate)
correlated and GUs
incorporated
Treatment outcome
(normal tissue complication)
correlated
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Static values regardless GUs
Not treatment outcome correlated
Model of geometric uncertainty may not
be representative
Not treatment outcome correlated
Parameter is ambiguous
Model may be oversimplified




Parameters are ambiguous
Model and GUs may be oversimplified




Parameters are ambiguous
Model and GUs may be oversimplified




Parameters are ambiguous
Model and GUs may be oversimplified




Parameters are ambiguous
Model and GUs may be oversimplified

4

General materials and methods for COP Study

This chapter describes some general materials and methods for the following COP studies
in chapter 5 and 6 to account for GUs like organ deformation and delineation uncertainties for
prostate cancer treatment. In section 4.1, the patient database and the basic settings of IMRT
planning are presented. In section 4.2, the software that implements the GU models in plan
optimization (e.g., COP) and evaluation is given. To evaluate the clinical role of COP, the
planning techniques to be compared with COP are introduced in section 4.3. The accuracy and
precision tests of coverage estimates used in the plan evaluation/comparison for each COP study
are discussed in section 4.4.
4.1 Patient database and IMRT planning
The patient database used in this dissertation is a 19-prostate cancer patient-cohort from
the Netherlands Cancer Institute (NKI). The patient database with 8-13 CT images throughout
the course of treatment per patient permits (a) reasonable confidence to do a population-based
research, (b) important GU information for modeling GUs in multi-fractional treatment for
prostate cancer representatively, e.g., different positions and shapes of ROI contours reveals
interfraction organ motion and deformation during treatment, and (c) the convenience to perform
treatment planning on any selected image to simulate virtual treatment courses with or without
IGART strategies.
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A brief description of this patient database is given here as more details can be found in
an earlier work (Deurloo et al. 2005). The patient disease stages are: T1, 3 patients; T2, 4
patients; and T3, 12 patients. (Please refer Table I, page 2 for NCCN groupings of prostate
cancer.) During a 7–8 week course of conformal radiotherapy, each patient received a planning
fan-beam computed tomography (FBCT) scan and multiple (8-12 and 11 on average) repeat
FBCT scans. The patient was instructed to empty his bladder and rectum and subsequently drink
250 ml of fluid one hour before the planning FBCT was taken and before each treatment fraction
started. The repeat FBCT scans were obtained within 30 min before or after the daily treatment
fraction. All FBCT scans (planning + repeat) were performed in same supine position on a flat
tabletop.
The original FECTs were per-patient boney-anatomy aligned, truncated to have the scene
number of slice 66–77 slices for each image set for each patient and resampled to have 3 mm
slice thickness, and 512 × 512 image resolution with voxel size 0.8 × 0.8 mm2. The scans cover
the anatomical regions from the upper part of the sacroiliac joints to 4 cm below the bottom of
the os pubis. For each FBCT image, the structures including prostate, seminal vesicles, rectum,
bladder, left femur and right femur were delineated by a single physician. As all the patients
were assumed to have high-risk prostate cancer in COP studies here, the target volumes CTVs
were prostate and seminal vesicles. No associated lymph nodes are included. The remaining
contoured structures (bladder, rectum, and etc.) were regarded as OARs, while the left and right
femur and the small bowel were excluded since their dose limits are rarely violated due to their
further distance to CTVs than the bladder and rectum.
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Figure 15. A transverse view of IMRT plan settings shared in COP studies: a typical seven-beam
arrangement (red lines) with the beam isocenter located at prostate centroid (small red circle in the
middle). The dose grid that always covers prostate (red contour), seminal vesicles (green contour), bladder
(yellow contour) and rectum (magenta contour) is indicated by the dashed green box.

For IMRT planning purposes, one FBCT (usually the first image, but the second image
for patient C) was selected for each patient as the reference image and the other FBCT images
were called fractional images. On each reference image (e.g., Figure 15), contours of seminal
vesicles, rectum and bladder were modified slightly to eliminate overlapping region with prostate
and with each other. The treatment plan utilizes seven coplanar (transverse) photon beams with
gantry angle 30, 80, 130, 180, 230, 280, 330º. The beam isocenter was set to the centroid of
prostate (=GTV=CTVprostate). A dose grid was created based on a volume expanded from union
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ROI (prostate + seminal vesicles + rectum + bladder) by 30 mm. This dose grid size ensures all
the ROIs and regions of uncertainties are covered, while excluding the unnecessary regions to
reduce dose calculate time and reduce computer memory usage.

The dose grid resolution is

either 2×2×2 mm3 or 3×3×3 mm3, depending on which COP study is being performed. For
planning optimization to account for interfraction deformable motion (chapter 5), the dose grid
resolution is 3×3×3 mm3. The remainder studies use 2×2×2 mm3.
4.2 Software (GUI) for COP study
Software for the COP study refers to (i) dynamic libraries (plugins) in Pinnacle3 which
incorporate several GUs models to perform COP and related probabilistic evaluation and
optimization and (ii) a graphical user interface (GUI) that allows users to interact with Pinnacle3
via a more user-friendly interface than text. This software implements COP theory (chapter 2) in
a TPS that is realistic and convenient. This section focuses on the GUI.
The dose-volume-coverage (DVC) GUI is a multi-functional tool with embedded plugins
for Pinnacle3 for the convenience of both developers and ordinary treatment planners. It serves
as a bridge between the TPS and the developed plugins.
The functions of GUI have been extended. Multiple GU models have been developed to
perform the COP optimization (mentioned in chapter 2) and the optional probabilistic plan
evaluation based on the dosimetric/biological metrics (described in chapter 3). The results of
these metrics can be displayed graphically in the GUI, allowing an efficient plan
evaluation/comparison. Each function is associated with a GUI tab, whose details are listed in
Table VII. How to use different GUI tabs for different purposes is illustrated in Figure 16 and
the screen shots of all the functioning tabs are shown in Figure 17 and Figure 18.
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Table VII. The main functions of the functioning tabs of DVC GUI
Tab 1: “Optimization” (chapter 2)


Specify/load optimization criteria in TPS



Error check: bad weight, bad format of a research objective

Tab 2: “GU models” (II and IV are included in chapter 5 and 6 ,respectively)


Specify geometric uncertainty model and parameters
I.
II.
III.
IV.



RigidBodyNormal (for setup errors or rigid organ motion)
PCAdvfModel (for deformable organ motion)
PCA+ RigidBodyNormal (a combination of the above two models)
DelineationModel (for delineation uncertainties)

Error check: bad parameter file that is inconsistent with the selected GU model and each structure can have
only one GU model.

Tab 3: “Endpoint” (chapter 3)


Specify endpoint model for biological metrics
I. TCP_Poisson (TCP Poisson model using physical dose or BED)
II. TCP_PoissonEud (TCP Poisson model using physical dose or BED-based gEUD)
III. NTCP_LKB_ErfEud (NTCP LKB model using physical dose or BED-based gEUD)



Error check: bad parameter file that is inconsistent with the selected endpoint model

Tab 4: “Evaluation” (chapter 2 and 3)


Specify DVHs/pDVHs to be plotted in the DVHs/PDVHs tab



Error check: bad DVH/pDVH metric name

Tab 5: “DVHs/PDVHs”


Show DVHs/PDVHs of ROIs on the trials of interest

Tab 8: “Outcome”


Show box plot of TCP/NTCP distribution of ROI on the trials of interest.
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Figure 16. DVC GUI flow for performing COP or margin-based treatment planning (MP) +/probabilistic plan evaluation by computing and plotting specified pDVHs and/or TCP/NTCP distribution.
Colored arrows indicate the flow for the item listed in the same color. The details are described in the
text.
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Figure 17. Interface of DVC GUI tabs: (upper) Tab 1 “Optimization” which is used to set the criteria used
for optimization; (middle) Tab 2 “ GU Models” used to set the GU models used for COP optimization or
plan probabilistic evaluation; (lower) Tab 3 “End Points” used to set the TCP/NTCP model and
parameters to calculate TCP/NTCP distribution for probabilistic evaluation and plot it in “Outcomes”
tab. The primary GUI design is done by Dr. John James Gordon. (copyright JJ Gordon 2011©, copyright
H Xu 2013©)
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Figure 18. Interface of DVC GUI tabs: (upper) Tab 4 “Evaluation” that determines the pDVHs to be
plotted in “GU Models” tab; (middle) Tab 5 “ GU Models” that plots pDVHs of multiple ROIs on
multiple trials (plans) with criteria highlighted as triangles. Here, dose is displayed in the unit cGy
while 1 cGy = 0.01 Gy. (lower) Tab 8 “Outcomes” that plots distribution of TCP and NTCP for
multiple ROIs on multiple trials (plans). For both Tab 5 and Tab 8, legends are displayed on the left
showing pDVH or TCP/NTCP of different ROIs (with different color) on different trials (solid or
dashed). (copyright JJ Gordon 2011©, copyright H Xu 2013©)
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4.3 Planning techniques for comparison
The planning techniques to be compared with COP in this dissertation utilize PTV
margins to accommodate GUs of CTVs. The PTV margins are either empirically predefined or
optimized based on the target coverage evaluation. These techniques are also generally called
margin-based planning techniques in the following text.

Figure 19. Workflow of COP versus OM and FM planning technique to account for GUs e.g., interfraction
organ deformable motions for high-risk prostate cancer patients. Abbreviation: tgt = target, SV = seminal
vesicles, PTV1 = CTVprostate + PTV margin of CTVprostate and PTV2 = CTVSV + PTV margin of CTVSV. The
PTV margins used in FM for all the patients are empirically determined based on literature. Here, 5mm
for PTV1 and 8mm for PTV2 are an example for the study to accommodate interfraction organ deformable
motions.

The two margin-based planning techniques used for planning comparison with COP are
called optimized-margin planning technique (OM) and fixed margin planning technique (FM).
The workflow of COP, OM and FM are illustrated in Figure 19. To generate a dose distribution
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intended to accommodate GUs for CTVprostate and CTVSv, both OM and FM rely on PTV
structures (PTV1 and PTV2 for CTVprostate and CTVSv, respectively) and the DVH objectives.
COP does away with PTVs and utilizes the pDVH objectives for dose optimization.
FM is a basic PTV-based treatment planning technique similar to the conventional
margin-based planning method where pre-defined PTV margins are determined empirically. In
the following studies, PTV margins for CTVprostate and CTVSV are determined by either a
published work (as shown in Figure 19) or van Herk margin formula (van Herk et al. 2000).

Figure 20. Flow diagram of margin iteration of the OM planning technique used in this dissertation. The
PTV margins for CTVprostate and CTVSV are initialized as 0mm and then iteratively adjusted to achieve
prescribed D98,95 for both CTVprostate and CTVSV. PTV margin is increased by 1mm for the next iteration
for any CTV whose D98,95 is lower than the prescribed value. If one CTV achieves prescribed D98,95 while
the other fails, PTV margin for the CTV with desirable D 98,95 remains the same in the next iteration.

Compared to FM, OM is an advanced PTV-based planning technique which was proposed
(Gordon and Siebers 2009) to optimize the uniform PTV margin(s) for each patient to meet the
target dose at prescribed coverage D98,95. As Figure 20 shows, OM used in this dissertation starts
with 0 PTV margins for CTVprostate and CTVSV and iteratively increases PTV margin(s)
uniformly by increment 1mm until both CTVs achieves prescribed D98,95. In each iteration,
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D98,95 values are estimated based on the dosimetric consequences of 1000 virtual treatment
courses with GU model incorporated.

In the contrast that COP considers OAR coverage

probability and generates dosimetric margins which are often only achieved by non-uniform
PTV margins, OM is less complicated and more emphasized on CTV coverage when adjusting
PTV margins.
4.4 Sensitivity of coverage estimates to treatment courses sampling
In the COP studies of this dissertation, probabilistic evaluation of treatment plans are
based on the 1000 virtual treatment course simulations. The inherent assumption is that the
resulting pDVH and associated dose coverage metrics estimated from 1000 virtual treatment
course is of acceptable accuracy and precision.

This section shows the testing results to

consolidate this assumption.
4.4.1

Accuracy tests

The estimation accuracy of the metric Dv,q (dose delivered to volume v at coverage
probability q) is tested via checking how Dv,q value converges using different number of virtual
treatment courses. Denote Dv,q_Ntx the estimated Dv,q based on Ntx virtual treatment courses.
|Dv,q_1000|, the absolute percentage difference of Dv,q_Ntx relative to Dv,q_1000 is calculated as
| Dv , q _1000 |

Dv ,q _1000  Dv ,q _ Ntx
Dv ,q _1000

 100%

(33)

The smaller |Dv,q_1000| is, the better Dv,q_Ntx converges to Dv,q_1000.
In terms of target structures CTVprostate and CTVSV of two patients with ID A and S,
|D98,95_1000| has been calculated for the zero-PTV-margin plans and COP plans evaluated via
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Ntx = 10, 100, 200 and 500 virtual treatment courses with PCA or ASSD model5 incorporated.
As Figure 21 illustrates, |D98,95_1000| is reduced to 0.2% or lower when Ntx increases from 0 to
500, which reveals an acceptable convergence relative to Ntx = 1000.

Figure 21. |D98,95_1000| of CTVprostate (red) and CTVSV (green) as a function of Ntx (number of simulated
virtual treatment courses) for the zero-PTV margin plan ((a),(c)) and the COP ((b),(d)) plan of patient A
(solid lines) and S (dashed lines). The patient-specific PCA model is incorporated to consider deformable
motions in (a) and (b) while the patient-specific ASSD model in incorporated to consider delineation
uncertainties.

For OAR, |Dv,q_1000| is plotted in Figure 22 when Ntx = 500 is used for the zero-PTVmargin plans and the COP plans evaluated with PCA or ASSD model incorporated for patient A
and S. In the high dose region where v of Dv,q is small, |Dv,q_1000| remains within 1% and
mostly < 0.5%.

In general, |Dv,q_1000| of COP plan is smaller than that of zero-PTV-margin

plan. In the low dose region where v of Dv,q is large, |Dv,q_1000| tends to be larger. As low dose

5

PCA (principal component analysis) and ASSD (average-surface-of-standard-deviation) are two methods
for modeling organ deformation (chapter 5) and delineation uncertainties (chapter 6). Readers are referred to section
5.2.2 and 6.1.1 for the details of these models.
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region is of less interest in terms of dose sparing and OAR toxicity, OAR Dv,q_1000 shows
acceptable convergence for the test cases.

Figure 22. |Dv,q_1000| of OAR of Patient A (left) and S (right) when Ntx = 500. |Dv,q_1000| is obtained for
COP plan (blue) and zero-PTV-margin plan (red) with the PCA model incorporated consider deformable
motions, and COP plan (green) and zero-PTV-margin plan (purple) with the ASSD model incorporated to
consider delineation uncertainties. |Dv,q_1000| is small in the high dose region and gets larger in the low
dose region.

4.4.2

Precision tests

The precision of the Dv,q value calculated previously is tested via checking the
reproducibility of Dv,q values repeatedly estimated by 1000 virtual treatment courses. Denote
Dv,q_No.n the Dv,q based on nth repeated estimation. | Dv,q,precision | , the absolute difference of
Dv,q_repeat,n relative to one estimated Dv,q, is calculated as
| ΔDv,q,precision |

Dv,q  Dv,q_No.n
 100%
Dv,q

(34)

The smaller | ΔDv,q,precision | is, the more precise/reproducible Dv,q is. Here, Dv,q = Dv,q_No.1.
The maximum | Dv,q,precision | ( | Dv,q,precision |max ) among all the repeated estimated
| Dv,q,precision | is calculated for the zero-PTV-margin and COP plans with PCA or ASSD model

incorporated for patient A and S in Table VIII. The | Dv,q,precision |max of CTVprostate/CTVSV
remains lower than 0.2% / 0.3% while ranges from 0.0% to 3.5% for OAR. In general, Dv,q is
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more precise in high dose regions. Dv,q for the COP plan is more precise than that for the zeroPTV-margin plan.
Table VIII. The | Dv,q,precision

|max based on repeated estimation of Dv,q for 7-10 times for the zero-PTV-

margin plan and the COP plan with PCA/ASSD model incorporated for Patient A and S.

| Dv,q,precision |max (%)
Deformable motions (PCA)
zero-PTV
COP
A
S
A
S
CTVprostate D98, 95
CTVSV D98, 95
Bladder D2,5
Bladder D9,5
Bladder D14,5
Bladder D20,5
Bladder D30, 5
Bladder D50, 5
Bladder D70, 5
Rectum D2, 5
Rectum D5, 5
Rectum D20, 5
Rectum D30, 5
Rectum D50, 5

0.1
0.0
0.2
0.2
0.3
0.4
0.6
0.6
0.1
0.2
0.4
0.2
0.2
0.1

0.1
0.2
1.0
1.7
1.8
1.6
1.6
3.5
0.7
0.9
0.7
0.9
1.0
0.1

0.1
0.0
0.1
0.1
0.2
0.3
0.5
1.0
0.1
0.1
0.2
0.3
0.3
0.1

0.1
0.0
0.0
0.1
0.1
0.2
0.7
1.4
0.1
0.2
0.3
0.9
1.4
0.1

Delineation uncertainties (ASSD)
zero-PTV
COP
A
S
A
S

0.1
0.2
0.8
1.1
0.3
0.1
0.1
0.3
0.3
0.2
0.0
0.0
0.1
0.1

0.3
0.1
0.2
0.3
0.4
0.1
0.1
0.6
0.3
0.3
0.1
0.1
0.2
0.3

0.1
0.1
0.1
0.1
0.1
0.1
0.6
0.5
0.2
0.1
0.1
0.1
0.1
0.1

0.3
0.0
0.1
0.2
0.2
0.2
0.2
0.0
0.1
0.1
0.1
0.0
0.0
0.3

Figure 23. The repeated estimated pDVHs 95% (solid lines) and 5% (dashed lines) of CTV prostate (red),
CTVSV (green), bladder (yellow) and rectum (magenta) based on the simulations using 1000 virtual
treatment courses repeated for 7 times. The differences between the repeated pDVHs are very small.

Example.
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The repeated estimated pDVHs 95% and 5% with PCA model incorporated for zeroPTV-margin plan for patient S are plotted in Figure 23.

Even with relatively large

| Dv,q,precision |max in the low dose region, the difference between the repeated pDVHs is hardly

noticeable, so the reproducibility of coverage estimation using 1000 virtual treatment courses is
acceptable.
Based on the above testing results, the assumption that the pDVH and associated dose
coverage metrics estimated from 1000 virtual treatment course is acceptably accurate and precise
is consolidated.
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5

COP to account for interfraction deformable motions

For prostate cancer, interfraction organ displacement and deformation occur due to the
bladder and rectal filling and are seemingly random as no expansion/shrinkage occurs due to
disease progression/regression. The uncertainties caused by interfraction deformable motion
were found to be common and can be significant during the treatment course. (Mah et al. 2002,
van Herk 2004, Byrne 2005, Kerkhof et al. 2008, Peng et al. 2010)
In conventional margin-based planning, there is not a recommended method determine
the size of PTV margin to account for CTV and OAR interfraction organ variations. The
commonly used margin recipes (Stroom et al. 1999, van Herk et al. 2000) derived for the
assumed rigid motion are not applicable to deformable organ motion, which are of a much higher
dimensionality than the six parameters of shifts and rotations. The dosimetric consequence of a
margin may vary with factors such as localization and immobilization methods, patient anatomy,
treatment protocol, plan quality and beam arrangement. Although CTV-to-PTV margin size for
prostate and seminal vesicles has been suggested in some studies (Meijer et al. 2008, Mutanga et
al. 2011), they should be used with caution.
Compared with the conventional margin-based planning, COP may have the potential to
either further improve the target coverage probability by raising OAR doses within tolerance or
reducing OAR normal tissue toxicity with comparable target coverage in the presence of
different GUs. (Gordon and Siebers Unpublished, Gordon et al. 2010) This chapter concentrates
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on the application of COP to account for organ interfraction deformable motion in the clinical
scenario where IGRT for prostate centroid alignment is utilized. The prostate plans and GU
models used for this study are described first. Then the research results of dosimetric effect and
plan optimization with GU model incorporated are discussed to explore potential clinical benefit
of COP.
5.1 Prostate plans
As previously mentioned, 19 NKI patients are involved in this study. For each patient,
one of the bony aligned FBCT images was selected as reference image set for planning. On this
image set, a series of 7-beam IMRT plans were generated either based on COP or the two
margin-based techniques for comparison. Other details of patient database and IMRT plans are
referred to section 4.1 (page 52).
Two CTVs, CTVprostate (= prostate) and CTVSV (= seminal vesicles), are for treatment,
since all the patients are assumed with high-risk prostate cancer. The prescription dose to the
prostate is 2.6 Gy/fraction for 30 fractions, which is biologically equivalent (equation (27)) to
2 Gy/fraction for 43 fractions used in a VCU protocol. The optimization criteria are listed in
(Table III, page 22).

The two critical OARs are the bladder and the rectum. The

norm_tissue_ring is an artificial structure extending from 7 to 30 mm from CTVprostate and
CTVSV to force a steep dose drop-off.

CTV_neighborhood is another artificial structure

extending by 12mm from the union volume of CTVprostate and CTVSV on all image sets. This
structure is purely used to set initial beam fluence for COP implementation in Pinnacle3 (See
section 2.5.2). During optimization, CTV_neighborhood has no contribution to the objective
functions as its objective function weight is set to 0.
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The statistics of the patient-specific ROI volume changes based on the delineations on the
multiple image sets for each NKI patient are summarized in Table IX. Large percentage SD
relative to mean (%SD) indicates large magnitude of deformable motions involved in different
treatment fractions.
Table IX. The mean and the percentage SD relative to mean (%SD) of ROI volumes over all image sets for
each patient with ID A-S of the patient database

ID
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S

CTVprostate
mean
%SD
37
12
69
7
50
9
29
10
44
6
27
12
76
14
39
13
40
10
97
7
45
8
46
5
24
6
33
9
30
6
46
5
46
7
75
5
52
5

CTVSV
mean
%SD
17
22
14
14
28
14
10
15
10
11
11
9
9
16
17
14
15
15
19
11
12
10
7
17
13
6
13
3
8
9
8
11
19
8
18
8
11
11

Bladder
mean
%SD
277
45
287
31
220
34
230
38
176
54
110
31
412
18
224
45
142
29
127
26
211
35
212
50
160
56
174
26
128
46
109
21
166
37
237
49
143
31

Rectum
mean
%SD
106
24
132
34
84
22
71
25
74
37
54
23
72
32
103
44
84
30
67
24
59
29
78
28
65
25
104
30
55
29
83
30
60
37
87
27
77
11

5.2 GU models for deformable organ motions
Two candidate models to represent deformable organ motions are studied in this work.
Both models intend to predict ROI voxel positional offsets in the patient coordinates caused by
deformable motion under the condition that CTVprostate centroid is aligned. The simpler one is
called the simple surface variation (SSV) model. The more sophisticated one is based on
principal component analysis (PCA). The SSV model is constructed first to see if it represents
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the characteristics of variations of patient database. If not, the PCA model is then constructed
for modeling.
5.2.1

Simple surface variation (SSV) model

The SSV model is intended to give a first-order estimation of ROI geometry variability
using few variables as input. This rough model, dependent on a linear correlation between the
ROI centroid locations and volume, is used to guide necessity of finer linear model, i.e., PCA
model.

Figure 24. An illustration of how to obtain a new position of surface voxel of a ROI (other than CTVprostate)
(SROI’) based on a SSV model. As CTVprostate-centroid alignment is assumed, the centroid position of
CTVprostate, old as CCTVprostate and new as CCTVprostate’, is always known. By sampling a new position of the
ROI centroid (CROI’), the new centroid distance between ROI and CTVprostate` (CDROI-P’) and ROI centroid
offset (ΔCROI) can be calculated. Assume that ROI volume change (ΔVROI) is a function of CDROI-P’, ΔVROI,
and ΔCROI can be used to estimate the surface point change relative to old position (SROI) so that SROI’ can be
therefore determined. Abbreviation: P = CTVprostate

How the SSV model predicts an ROI surface position change due to deformable motions
is illustrated in Figure 24. The SSV model relies on a strong correlation (and therefore a simple
function) between the ROI-CTVprostate centroid distance (CDROI-P) and the ROI volume (VROI) as
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VROI  a(CDROI-P  c)b  d

(35)

where a, b, c, d are the parameters to fit using correlation and least-square fitting based on
information from the patient database. On each image set for each patient, CTVprostate volume
(VCTVprostate), ROI volume (VROI) and the position of ROI surface voxel ( S ROI ), ROI centroid
( CROI I), CTVprostate centroid ( CCTVprostate ) and their difference (CDROI-P) are known and can be
used to determine a, b, c, d . Therefore, the ROI volume change between the reference and the
fractional image sets becomes
ΔVROI  a[(CDROI-P  c)b  (CDROI-P ' c)b ]

(36)

where ' means a new value on the fractional image set. The SSV model also assumes that the
ROI radius rROI  3 ΔVROI , so the new ROI surface voxel position S ROI ' can be estimated by
SROI '  SROI  v(CROI'  CROI )  u( 3 ΔVROI )

SROI'  CROI'
| S ROI'  CROI' |

(37)

where u, v are the parameters to fit based on data variation from the patient database.
Equation (37) means that S ROI ' is determined by three components: (1) the old position of ROI
S ROI , (2) the ROI centroid position change CROI'  CROI , and (3) the radius changes in direction

pointing from S ROI ' to CROI' . Assume the direction of S ROI relative to CROI remains unchanged
and substitute equation (36) into equation (37), we have
SROI '  SROI  v(CROI'  CROI )  u( 3 a[(CDROI-P  c)b  (CDROI-P '  c)b ])

SROI  CROI
)
| SROI  CROI |

(38)

For a CTVprostate-centroid-aligned treatment, the new CTVprostate centroid position ( CCTV-centroid ' ) is
always “known”. By sampling ROI centroid position ( CROI' ) from a PDF based on the patient
database, the new ROI surface voxel position S ROI ' can be calculated.
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To test if the SSV is valid for deformable organ motion, the mean and SD of correlation
coefficients of different volume and different centroid distance relative to CTVprostate across 19
patients are calculated in Table X. Only the bladder-CTVprostate centroid distance and bladder
volume show strong correlation (> 0.9), when parameter b = 1. Similar coefficient calculations
have been done for bladder wall and rectal wall, but none of them showed strong correlations.
When b is replaced by 2 and 3, the correlation coefficient does not change significantly for all
the structures.

For example, patient E has correlation coefficients of 0.947 for bladder

volume (VB) and bladder-CTVprostate centroid distance (CDB-P,z), 0.950 VB and CDB-P,z2 and 0.939
VB and CDB-P,z3. Based on the correlation coefficient, the SSV model has limited applications
for prostate cancer modeling and is only potentially useful to predict bladder deformable motion.
Table X: The mean and SD values of the correlation coefficients between volumes and centroid distances of
ROI for 19 NKI patients. Highly correlated variables are highlighted.
mean
SD
VB, CDB-P,z
0.943
0.039
VB, CDB-P
0.923
0.064
VR, CDR-P
0.427
0.447
VR, CDR-P,y
0.183
0.461
VB, CDR-P
0.149
0.425
VR, CDB-R
0.125
0.395
VR, CDR-P,z
0.100
0.426
VB, CDR-P,y
0.075
0.374
VR, VB
0.029
0.454
VB, VP
-0.063
0.369
VR, VP
-0.164
0.283
Abbreviations: VB: bladder volume; VR: rectum volume; VP: CTVprostate volume; CDB-P,z: centroid distance
between bladder and CTVprostate in z axis; CDB-P: centroid distance between bladder and CTVprostate; CDR-P: centroid
distance between rectum and CTVprostate; CDR-P,y: centroid distance between rectum and CTVprostate in y axis.

For the bladder SSV model, the residual error of bladder volume in equation (35) with
fitted parameters based for an individual patient can be significant. In Figure 25 (a), the bladder
volume residual error using fitted parameters specific for patient E is about 50 cc for a 200 cc VB
and therefore the surface position error, if comparable to radius difference, is approximately
3mm. For each patient, the residual error as a result of each patient-specific fitting is plotted into
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a population-based histogram and fitted by a normal distribution. The SD of this fitted normal
distribution is 27 cc, so the uncertainty for VB is ±54 cc for a 95% confidence interval. Based on
these numbers, the SSV model is oversimplified and not representative for modeling organ
deformable surface positions for prostate cancer patients. A higher dimensional model, i.e., PCA
model, is needed to represent more realistic organ deformable motions in the prostate cancer
studies.

Figure 25. (a) (Upper panel) The linear, quadratic and cubic fitting of centroid distance between bladder
and prostate in z axis CDB-P,z to bladder volume VB. (Lower panel) The corresponding residual error for
the three types of fitting. (b) Histogram of the distribution of residual error over 19 patients and its
general Gaussian fit.

5.2.2

Principal component analysis (PCA) model

PCA is a mathematical procedure that uses an orthogonal transformation to convert large
complex data sets of possibly correlated variables into a set of values of linearly independent
variables called principal components.

Based on a few deformable-registration-based

displacement vector fields (DVFs) of organ geometry, PCA can create a low-dimensional
parametric statistical organ deformation model to generate a synthetic DVF (Söhn et al. 2005b),
which is representative of the possible organ deformation on a virtual treatment fraction. The
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residual errors of a PCA model for prostate, bladder and rectum were small, e.g., less than 2mm
when eigenmodes representing more than 86% overall variability were used. (Söhn et al. 2005b)
As an earlier study stated (Söhn et al. 2012), PCA is a practical model to generate DVFs used to
simulate anatomies for a large number of virtual treatment courses, thereby allowing the
comprehensive assessment of dosimetric effects caused by deformable GUs (i.e., for the
applications of COP or probabilistic plan evaluation in this dissertation).

Figure 26. Illustration of a DVF between reference image set R and fractional image set F and dose
mapping process. Due to the effects of GUs, the shape and position of a ROI change on different image
sets (i.e., elliptical on R and triangle on F). Image R and F are not necessarily in the same domain.
Denote g and h the coordinates in image R and F, respectively. The geometric transformation between g
and h are represented by DVF(g) in the equation g + DVF(g) = h, which relates the intensity R(g) and
F(h). For the dose mapping, dose to h is mapped back to g for i.e., dose accumulation of a multifractional treatment course.

The DVF created by PCA is a vector field that matches corresponding ROI voxel
positions in a reference image set R to a synthetic fractional image set F. As Figure 26 shows, a
DVF grid on the reference image set needs to be determined first to store a displacement vector
for each DVF voxel. (The DVF grid used here is a little different from image grid and dose grid,
so interpolation is required during conversion of the grids.) The DVF between R and F is
computed by a deformable registration algorithm called Small Deformation Inverse Consistent
Linear Elastic (SICLE) (Christensen and Johnson 2001). Based on the information of CT
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intensity and ROI delineation, SICLE matches ROI coordinates in R and F, thereby determining
the DVF for the whole DVF grid. Let g and h denote the coordinates of voxels on R and F.
The relationship between g and h and DVF( g ) is
h  g  DVF( g )

(39)

The DVF( g ) accounts for both affine and deformable transformations with respect to anatomies
represented in R.
INPUT:

N DVF bony-aligned DVFs,
each with N vox Voxels, written
as matrix DVFmat
(equation (40))

Random DVF: DVFrand (equation (42))
Covariance C (equation (43))
Systematic DVF
DVFsyst

Get eigenvector EV and eigenvalue 

(equation (41))
Determine L for top EV (equation (46))
Sample c for EV from PDF based on KDE

OUTPUT:
Synthetic bony-aligned DVF:
DVFsyn (equation (50))
or
Synthetic GTV-aligned DVF:
DVFsyn _ Paligned (equation (51))

Figure 27. Workflow of construction of a patient-specific PCA model. KDE=kernel density estimator.
See the following text for detailed description.
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The workflow of a patient-specific PCA model is illustrated in Figure 27. The purpose of
using the PCA model is to create synthetic DVFs that represent anatomical deformable motions
likely to occur in virtual treatment courses. For a patient with N FBCT (= 9-13) FBCT images, the
number of training set DVFs is N DVF (= N FBCT –1) for ( N FBCT –1) repeat FBCT images mapping to
the reference planning FBCT image. These N DVF DVFs, each with N vox DVF voxels, are written
into a matrix DVFmat 

3 Nvox  N DVF

as a practical way for coding.

3 Nvox  N DVF

means that the size of

matrix DVFmat is 3Nvox (rows) by N DVF (columns) as follows,

DVFmat

x1,2
 x1,1

x2,2
 x2,1
 ...
...

 xNvox ,1 xNvox ,2

y1,2
 y1,1

y2,1
y2,2

 ...
...

 y Nvox ,1 y Nvox ,2

z1,2
 z1,1
 z
z2,2
 2,1
 ...
...

 z N ,1 z N ,2
vox
 vox

...
...
...
...
...
...
...
...
...
...
...
...

x1, N DVF 

x2, N DVF 

...

xNvox , N DVF 

y1, N DVF 

y2, N DVF 
... 

y Nvox , N DVF 

z1, N DVF 
z2, N DVF 


...

z Nvox , N DVF 

(40)

where x, y, z are the displacement vector field components or magnitude in the x,y,z directions
for each DVF voxel. DVFmat is then divided into a systematic component DVFsyst 
random component DVFrand 

3 Nvox  N DVF

3 Nvox 1

and a

. DVFsyst is the mean DVF of the N DVF DVFs for a given

voxel. DVFsyst represents the DVF which relates the patient’s average anatomy relating to the
reference image set.

DVFrand is obtained via subtracting DVFsyst from each fractional DVF
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( DVFmat (i) ) , which is i th column data of DVFmat . As Figure 27 illustrates, PCA manipulation is
performed on DVFrand . The equations to determine DVFsyst and DVFrand are

DVFsyst 

1
N DVF

 N DVF

  x1,i 
 i 1

 N DVF

  x2,i 
 i 1



...
N

 DVF

  xNvox ,i 
 i 1

 N DVF

  y1,i 
 i 1

N DVF


N DVF
1   y2,i 
DVFmat (i ) 

i 1

N DVF 
i 1

...
N

 DVF

  y Nvox ,i 
 i 1

 N DVF

  z1,i 
 i 1

 N DVF

  z2,i 
 i 1



...
N

 DVF

  z Nvox ,i 
 i 1


(41)

and
DVFrand  ...,DVFrand (i),... , DVFrand (i)  DVFmat (i)  DVFsyst
DVF(i) denotes DVF in i

th

(42)

column (for i th repeat FBCT) while i  1,2,..., N DVF . For DVFrand , the
N DVF  N DVF

implicit covariance matrix C 

that generalizes the notion of variance to dimensions

N DVF  N DVF (Murakami and Kumar Sept., Lorenz and Krahnstöver 2000) is

C

1
N DVF

N DVF

 DVF
i 1

rand

T

DVFrand
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(43)

where ( )T denotes the transpose of the matrix and ( )T  ( ) represents the outer product of the two
matrices. Then C is diagonalized as Cdiag
Cdiag  diag (1 , 2 ..., NDVF )

where l 

11

(44)

(with index l ) is called an eigenvalue.

eigenvector EV (l ) 

3 Nvox 1

During this diagonalization, each

corresponding to each eigenvalue is obtained. An eigenvector is

also called an eigenmode as it represents a DVF of correlated displacements of N vox voxels. All
the eigenvectors are mutually independent vector fields and the maximum number of
eigenmodes that exist is N DVF  1 . Therefore, the whole eigenvector matrix is EV 

3 Nvox ( N DVF 1)

.

To measure the fraction of overall geometric variability (present in the input DVFmat ) represented
by an eigenmode with index l , the relative eigenvalue l is calculated as
l  100% 



l
i 1,2,..., N DVF

i

(45)

which means the larger the eigenvalue is, the more dominating eigenmode it is due to capturing
more geometric variability in DVFmat . The total fraction of geometric variability  of L most
“principal” eigenmodes is
   i 1,2,..., L i

(46)

For each eigenvector, coefficients are found in a matrix Coeff 
product of DVFrand T 

N DVF 3 Nvox

and EV 

 c1,1


Coeff  (DVFrand )T ( EV )   c1,i


 c
 1, N DVF

3 Nvox ( N DVF 1)

, which is the

,

cl ,1

cN DVF 1 ,1

cl ,i

cN DVF 1 ,i

cl , N DVF

cN DVF 1, N DVF
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(47)

where i and l are the row and the column index of Coeff corresponding to DVFrand (i) and
EV (l ) . Based on this finite data sample of eigenvector coefficients Coeff , a PDF for the l

th

eigenvector can be estimated by kernel density estimation (KDE) (Rosenblatt 1956, Parzen
1962).

With a Gaussian kernel, each coefficient sample is made into a Gaussian, of SD,  .

The PDF is a continuous function as a result of superposition (sum) of Gaussians of all the
samples. An example of a KDE-based PDF and the Gaussians of samples is given in Figure 28.
For l th eigenvector, the PDF Pl of random variable t ranging from a to b is represented as

Pl [a  t  b] 

1

N DVF

N DVF   l  2

i 1

e

 t ci ,l 
2 l

2

2

(48)

where ci ,l is the matrix Coeff element in the i th row and the l th column in equation (47), and
the Gaussian SD  l is expressed as a rule of thumb equation (Silverman 1986)
N DVF

l 

1.06
N DVF 0.2

 (c

i ,l

i



1

N DVF

c

N DVF i
N DVF  1

i ,l

)2

With known eigenvectors and their PDFs of coefficients, a synthetic DVF, DVFsyn 

(49)

3 Nvox 1

, is

L

DVFsyn  DVFsyst   cl  EV (l )
l

(50)

where cl is the sampled coefficient for l th eigenmode sampled from the PDF in the form of
equation (48) based on rejection sampling. To create a DVFsyn that represent at least 90% overall
geometric variability, L is determined by   90% (Figure 29 (a)) and consequently ranges from
4 to 7 for 19 NKI patients (Figure 29 (b)). Since the input DVF are calculated for bony-aligned
anatomies on FBCT images, DVFsyn in equation (50) represents the interfraction deformable
motions relative to aligned bones.
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Figure 28. An example of coefficient PDF (black thicker line) for l th eigenvector based on KDE using
Gaussian kernels of the coefficient data samples (dashed lines). (Modified from Douglas Vile, VCU
graduate student)

Figure 29. (a) The total fraction of geometric variability  as a function of top eigenmode number with
90% threshold line to determine L . (b) Top eigenmode number L used for PCA model for 19 patients.

One concern of planning on a reference image of bony aligned anatomy is that large
margin for CTVprostate is often required to account for prostate motion and deformation relative to
bones. To effectively reduce the fractional anatomical deformation, a reference image set of the
average patient anatomy is preferred for planning. However, this is unlikely to happen. It is
nearly impossible to find the patient in such a state for imaging, or it requires repetitive imaging
prior to therapy which is not feasible in clinic. With the development of IGRT, a prevalent
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image-guided technique provides alternative solution for more precise target localization —
prostate centroid alignment.

This technique is clinically feasible and widely used since

implanted gold markers or Calypso beacons are safe and reliable for tracking the centroid
prostate on a fractional or even real-time basis. Because of this, the deformable motion to be
considered during treatment planning is reduced for the prostate. As Figure 30 shows, in a
CTVprostate-centroid-alignment based plan, the dosimetric degradation and variability due to
deformable motion on CTVprostate is smaller than the bony-aligned plan and mean geometrybased plan. This technique, however, does not necessarily reduce the dosimetric degradation or
variability for CTVSV or OARs.
To simulate deformable organ motions for treatment with CTVprostate-centroid-aligned, the
bony-aligned DVFsyn in equation (50) needs to be modified. Let the vector element of DVFsyn
represented by ( xsyn,i , ysyn,i , zsyn,i ) where i  1,2,..., Nvox and denote synthetic xsyn, P , ysyn, P , zsyn, P as
displacement vector of CTVprostate centroid. The synthetic DVF for CTVprostate-centroid-aligned
anatomies DVFsyn _ Paligned 

3 Nvox 1

is

DVFsyn _ Paligned

 xsyn ,1  xsyn , P 


 xsyn ,2  xsyn , P 


...


 xsyn , Nvox  xsyn , P 
 y y

syn , P 
 syn ,1
 ysyn ,2  ysyn , P 


...


 ysyn , N  ysyn , P 
vox


 zsyn ,1  zsyn , P 
 z

 syn ,2  zsyn , P 


...


 zsyn , Nvox  zsyn , P 
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Figure 30. A patient example of pDVH comparisons of zero PTV-margin plans planned (upper) on the
CTVprostate centroid aligned anatomy (COM: thick lines) versus on the mean geometry (Mean: thin lines),
and (lower) on the CTVprostate centroid aligned anatomy (COM: thick lines) versus bony aligned anatomy
(Bony: thin lines). pDVH is obtained from 1000 virtual treatment courses. For target structures
CTVprostate (red) and CTVSV (green), pDVH 95% is desired to lie upper or right to the objective values
which are denoted by right triangle of corresponding color. For rectum (magenta) and bladder (orange),
pDVH 5% is desired to lie lower or left to the objective values which are denoted as the right triangle of
corresponding color. pDVH 95% and pDVH 5% are both plotted for each structure to examine the 90%
confidence interval of DVH distribution with PCA model incorporated.

To highlight the effect of small versus large random DVF variations on the dose coverage
probability, the dosimetric effect of using original PCA modeled DVF ( DVFsyn _ Paligned ) versus 5times magnified DVF ( 5DVFsyn _ Paligned ) is compared in Figure 31.
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Figure 31. A patient example of pDVH 95%(solid) and pDVH 5% (dashed) of zero PTV-margin plans
obtained from 1000 virtual treatment courses using 1 times (thick) versus (thin) 5 times magnitude of
PCA-modeled synthetic DVF for a CTVprostate-centroid-aligned anatomy.

In the following COP study, DVFsyn _ Paligned is utilized to simulate the synthetic ROI voxel
offset under the influence of organ deformable motions.
5.3 Decision flow to use COP
With a constructed PCA model, prostate plans can be evaluated and optimized to account
for the effects of interfraction deformable organ motion. To investigate the clinical value of
COP in terms of the resulting coverage probability and TCP/NTCP distribution, a treatment
planning decision flow shown in Figure 32 was designed. This decision flow exists to address
two concerns: (1) COP may not be necessary when dosimetric effect of GUs is insignificant and
(2) how to determine the clinical advantages of a COP plan relative to the PTV-based plans using
empirically determined PTV margins and optimized PTV margins based on target coverage
probability.
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Figure 32. Decision flow of COP to optimize treatment plans to consider organ deformable motions for
prostate cancer patients compared with optimized margin (OM) and fixed margin planning techniques.

Figure 32 shows the flow used for each patient. First, the dosimetric effect of PCAmodeled deformable organ motion is evaluated for the CTVprostate-centroid-aligned daily
fractions. A zero-PTV-margin IMRT plan is created based on optimization criteria for PTVbased plan in Table III (page 22) where PTV1 = CTVprostate and PTV2 = CTVSV. By simulating
1000

6

virtual treatment courses (30 fractions per treatment course) with PCA model

incorporated, the DVCM is constructed and the target dose-volume metric D98 at prescribed
coverage probability 95% (D98,95) is computed for both CTVprostate and CTVSV. Bladder and
rectum are excluded in the zero-PTV-margin evaluation because they are assumed to be
6

The analysis of accuracy and precision of ROI coverage estimated by 1000 virtual treatment courses has
been presented in chapter 4, section 4.4.

84

maximally spared relative to the non-zero PTV or COP plans. Denote D98,95,Rx as the prescribed
dose 78 Gy for CTVprostate and 66 Gy for CTVSV. If D98,95  D98,95,Rx for both CTVprostate and
CTVSV, the dosimetric effect of deformable organ motions for this patient will be regarded as
insignificant since target coverage probability is resistant to anatomical variability. Otherwise,
replanning the plan to further improve target coverage probability is required. In this case, COP,
OM and FM are performed. Here, FM utilizes fixed PTV margins for all the patients — 5 mm
for CTVprostate and 8 mm for CTVSV based on a published work (Mutanga et al. 2011). The best
plan among COP, OM and FM plans is determined by comparing their coverage probabilities
primarily. If the target coverage probabilities of these plans are very close, TCP/NTCP
distributions are examined for a secondary comparison.
5.4 Results
5.4.1

Dosimetric effects on zero-PTV-margin plans

The dosimetric effect of deformable organ motions reflected on the zero-PTV-margin
plans for 19 patients with prostate-centroid alignment is not insignificant. For the static plans
which are motion-free, the dose-volume based optimization criteria are not difficult to be
satisfied by a simple IMRT optimization. For the non-static plans when deformable motions are
considered and simulated in 1000 virtual treatment courses, the pDVH objective criteria for both
CTVprostate and CTVSV are not easy to achieve. The pDVH evaluation of each patient is shown in
Figure 49, in Appendix I.a. In Figure 33, the average pDVHs of 19 zero-PTV-margin plans are
plotted. Even with prostate centroid alignment, the mean CTVprostate D98,95 (red solid line) is still
lower than prescribed value (red triangle marker). Such dose degradation of CTVSV is even
more severe.

For bladder and rectum, the pDVH 5% (orange and magenta dashed lines)
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indicates some dose slack relative to OAR objective criteria can be exploited for margin
expansion to improve target coverage probabilities, though a few rectal Dv,5 have reached their
upper limit. According to the 90% confidence interval of the DVH (the gap between pDVH 95%
and 5%), DVH variability due to deformable motion for all ROIs are not large, probably due to
the blurring nature of random motions around the mean positions modeled by PCA.

Figure 33. The average pDVHs 95% (solid) and pDVHs 5% (dashed) evaluated on zero-PTV-margin
plans through 19 high-risk prostate cancer patients for anatomies CTVprostate (prostate) (red), CTVSV
(green), bladder (orange) and rectum (magenta) with optimization objectives (triangle markers). The
PCA model is incorporated to show the dosimetric consequence of organ deformable motions.

To determine the necessity of replanning using COP, OM or FM for each patient, the
percentage dose degradation %D98,95 is calculated.

%D98,95

 D98,95,Rx  D98,95
 100%

D98,95,Rx


0

(D98,95  D98,95,Rx )
(Else)

(52)

where D98,95,Rx and D98,95 represent prescribed and achieved D98 at 95% coverage probability.
The percentage DVH variability %DVH98,5-95 achieved D98 at 95% and 5% coverage
probability is
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%DVH98,5-95 

D98,5  D98,95
100%
(D98,5  D98,95 ) / 2

(53)

Both %D98,95 and %ΔDVH98,5-95 for 19 zero-PTV-margin plans are displayed in Figure 34.
The %D98,95 and %ΔDVH98,5-95 values are well correlated (Figure 35), with the correlation
coefficients 0.86 for CTVprostate and 0.90 for CTVSV.

Figure 34. (a) Percentage degraded dose (%ΔD98,95) and (b) DVH variability (%ΔDVH98,5-95) at
prescribed dose of CTVprostate (red bins) and CTVSV (green bins) for 19 zero-PTV-margin plans with
organ deformable motions considered (using PCA model).

On a patient-specific basis, the dosimetric effect of organ deformable motions is not
insignificant: 0/19 patients satisfy the D98,95,Rx objective for both CTVprostate and CTVSV as one or
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the other %D98,95 > 0%. The %D98,95 and %ΔDVH98,5-95 vary widely across the 19 patients.
The range of %D98,95 is 0.7-10.5% for CTVprostate and 0.0-28.3% for CTVSV. The range of

%ΔDVH98,5-95 is 0.2-2.3% for CTVprostate and 1.4-16.3% for CTVSV. Based on these results,
replanning using COP, OM or FM is required to achieve satisfactory D98,95 for the patients. In
other words, margins or some other accommodation must be made to account for the dosimetric
effects of deformable motions.

Figure 35. Scatter plot of percentage degraded dose (%ΔD98,95) versus DVH variability (%ΔDVH98,5-95) for
(a) CTVprostate (red dots) and (b) CTVSV (green dots) on 19 zero-PTV-margin plans evaluated with PCA
model incorporated for each patient.

5.4.2

COP plans vs. OM plans vs. FM plans

Among the COP, OM, FM plans generated for each patient, either (12/19) OM plans or
(7/19) COP plans are preferred, while the relative advantages between each other are patient
specific. This comparison result is based on the achieved dose at specified coverage probabilities
primarily and P+ (probability of complication free control) value secondarily. As a singlenumber substitute to represent complicated statistics of TCP/NTCP distribution, P+ is expressed
as
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P   E TCPprostate   1  E  NTCPrectum   1  E  NTCPbladder 

(54)

where E[] signifies the mean (i.e., expectation) value from the 1000 treatment course
simulations. The details of dosimetric/biological metric comparison between COP, OM and FM
are summarized in Table XI. The pDVH comparison of each individual patient is shown in
Figure 50 of Appendix I.b.
Table XI. Patient ID, percentage target dose degradation %ΔD98,95 for CTVprostate (P) and CTVSV (S), the
optimized PTV margins obtained by OM technique, and best planning technique and its gain relative to the
other two plans in terms of target dose coverage(D98,95) , normal tissue coverage (Dv,5) and probability of
complication free control P+. ID with */ † / ‡ denotes COP / OM / FM plan that fails to achieve target D98,95
ID
A*
B*†‡
C*
D*‡
E*
F*
G
H*
I*†‡
J*†‡
K‡
L†‡
M
N
O*
P‡
Q*
R*†‡
S

%ΔD98,95(%)
P: 4.9 S: 14.5
P: 5.8 S: 6.4
P: 5.3 S: 1.3
P: 7.7 S: 14.4
P: 1.3 S: 8.5
P: 0.8 S: 8.5
P: 2.2 S: 0.0
P: 1.7 S: 0.0
P: 2.9 S: 16.9
P: 11.1 S: 24.7
P: 9.5 S: 0.0
P: 7.5 S: 9.8
P: 2.7 S: 31.4
P: 0.8 S: 32.9
P: 0.8 S: 0.0
P: 2.4 S: 0.0
P: 3.1 S: 24.8
P: 2.6 S: 4.6
P: 0.7 S: 0.0

OM PTV (mm)
P: 2 S: 8
P: 10 S: 5
P: 5 S: 3
P: 5 S: 3
P: 2 S: 6
P: 1 S: 3
P: 2 S: 0
P: 4 S: 3
P: 6 S: 18
P: 7 S: 15
P: 9 S: 0
P: 9 S: 5
P: 5 S: 4
P: 4 S: 8
P: 1 S: 0
P: 2 S: 2
P: 3 S: 5
P: 4 S: 4
P: 2 S: 0

best plan
OM
OM
OM
OM
OM
OM
COP
OM
OM
COP
COP
COP
OM
OM
OM
COP
OM
COP
COP

Gain relative to the other plans
COP (target D98,95) FM (+6.5% P+)
COP (target D98,95) FM (target D98,95)
COP (target D98,95) FM (+2.8% P+)
COP (target D98,95) FM (target D98,95)
COP (target D98,95) FM (+11.9% P+)
COP (target D98,95) FM (+21.5% P+)
OM (OAR, Dv,5)
FM (+4.2% P+)
COP (target D98,95) FM (+0.9% P+)
COP (target D98,95) FM (target D98,95)
OM (target D98,95)
FM (target D98,95)
OM (+5.9% P+)
FM (target D98,95)
OM (target D98,95)
FM (target D98,95)
COP (+2% P+)
FM (+3.1% P+)
COP (OAR, Dv,5)
FM (+3.3% P+)
COP (target D98,95) FM (+22.8% P+)
OM (+ 1.7% P+)
FM (target D98,95)
COP (target D98,95) FM (+9.5% P+)
OM (target D98,95)
FM (target D98,95)
OM (OAR, Dv,5)
FM (+6.4% P+)

For the 7 best COP plans and the 12 best OM plans, the clinical benefit with respect to
the other plans is patient-specific, and is due to either target coverage or OAR sparing. Relative
to FM plans, 5/7 COP plans and 3/12 OM plans improve target D98,95 value, and 2/7 COP and
9/12 OM plans achieve better OAR sparing. When COP and OM compete with each other, 3/7
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COP plans versus 10/12 OM plans have better target D98,95 values. 4/7 COP plans versus 2/12
OM plans reduce more OAR dose.
As to the primary plan comparison metric coverage probabilities, 7/19 COP plans, 14/19
OM plans and 11/19 FM plans meet the optimization criteria of target coverage probability
D98,95. COP is most likely to fail the prescribed D98,95 because the target dosimetric margins are
constrained by the bladder and rectum, whose dose tolerance is often pursued in the expense of
degrading the target dose. After COP optimization using the pre-selected objective weights, the
target D98,95 is sometimes compromised at some level below D98,95,Rx to minimizes the composite
objective value (equation (2)) when the OAR Dv,5 terms are non-zero. The %ΔD98,95 of a COP
plan is mostly within 1% but can be up to 4.1% for CTVprostate and 9.3% for CTVSV. The
relatively poorer target coverage probability is also reflected in the planning results using
COPOM, which generates COP plans starting from OM plans. In Table XII, the originally
satisfied target D98,95 values in 7 of 14 OM plans end up below D98,95,Rx after COPOM
optimization. About half of 19 COPOM plans further spare bladder and rectum with a P+ gain up
to 9.8%.
Table XII. Good, moderate and bad changes resulting from COPOM relative to OM
Changes

Target

OAR

Good

Push D98,95 up to D98,95,Rx : 0/5

Satisfy more Dv,5 criteria: 8/19
P+ gain: 9/19

Moderate

D98,95 remains D98,95,Rx : 8/14

Minor change in Dv,5 criteria: 4/19

D98,95 remains below D98,95,Rx : 5/5
Bad

Degrade the achieved D98,95 : 6/14

Violate more Dv,5 criteria: 7/19
P+ loss: 10/19

90

It seems surprising that 5/19 OM plans (for patient ID with † in Table XI) failed to
achieve target D98,95 criteria as the termination condition of OM iteration (Figure 20 on page 61)
should ensure target D98,95  D98,95,Rx . However, the result is reasonable as the large OM PTV
margins result in larger overlap volume of the PTV and bladder/rectum and consequently a tough
tradeoff needs to be balanced between these structures. Figure 36 shows the tendency of the
competing target and OAR dose at each prescribed coverage probability using different PTV
margins. Due to this challenge, increasing uniform PTV margins is not the universal solution to
ensure target coverage probability.

Figure 36. An example of increasing competition between target and OAR criteria with increasing PTV
margins during OM optimization. The target prescribed dose or the OAR tolerance dose is highlighted
in the same color as the achieved dose curve for each ROI criterion.

91

In FM plans, the fixed PTV margins — 5 mm and 8 mm selected for CTVprostate and
CTVSV — fails to achieve target D98,95,Rx for 8/19 cases. This failure is caused by the suboptimal margin size without considering patient-specific response to GUs. To avoid undesirable
target coverage probability or excessive OAR dose, a patient-specific margin is required to
customize individualized characteristics of patient anatomy, deformable organ motions, plan
quality, and etc.
On a population basis, COP and OM plans are comparable and both are better than FM
plans. As the average pDVH 95% for CTVprostate, CTVSV and average pDVH 5% for bladder,
rectum shown in Figure 37, COP spares more rectal dose while OM spares more bladder dose
relative to FM. The average P+ gain of COP and OM relative to FM is 1.1% and 3.1%,
respectively. This concludes that for the high-risk prostate cancer patients with prostate centroid
aligned, using the pre-selected objective weights from this study, the benefit of COP in treatment
planning is limited when patient-specific coverage-based uniform PTV margins can be
determined (via OM).

Uniform PTV margins iteratively optimized from 0 during OM

optimization are preferred over COP since COP fails to achieve target coverage probability due
to the concern of OAR coverage probability for deformable organ motions. The bottleneck of
COP relative to OM may be overcome by more advanced IGRT strategies. These strategies
effectively reduce the time scale, magnitude and effect of deformable organ motions be
accounted for during treatment planning (Jaffray 2007, Bujold et al. 2012), thereby allowing
smaller target margins, geometrically (PTV margins) or dosimetrically (DMs), to achieve
desirable target coverage probability and OAR sparing.
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Figure 37. For a population-based comparison, the average pDVHs of (upper) COP vs. OM plans and
(lower) COP vs. FM plans to account for deformable motions. For target structures CTV prostate and CTVSV,
pDVH 95% are the lower bound of target dose-volume metrics. For OAR structures bladder and rectum,
pDVH 5% are the upper bound of OAR dose-volume metrics.
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5.5 Conclusions
This chapter explores of dosimetric effect of patient-specific deformable organ motions
(via a PCA model) on 19 patients with prostate-centroid aligned throughout the treatment course
and describe the implementation of COP with the PCA model incorporated. For the purpose of
evaluating the clinical benefit of COP, the PCA model is also incorporated into plan evaluation
and OM technique for parallel planning comparison.
The dosimetric effect of deformable organ motions on 19 zero-PTV-margin plans are not
insignificant, so treatment replanning using COP, OM and FM techniques is performed.
Compared with FM technique that uses empirical fixed PTV margins for each patient, COP or
OM techniques result in either better achieved target dose coverage or less toxicity of normal
tissues because of using coverage-probability metrics as optimization criteria. The relative
advantage between COP and OM are patient-specific. For some patients, COP has limited
clinical benefit relative to OM due to poorly selected objective weights and consequently
compromised target coverage probability in the presence of deformable organ motions. The
bottleneck of COP may be compensated in a more advanced clinical scenario where deformable
organ motions are effectively reduced.
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6

COP to account for delineation uncertainties

As the “weakest link” of GUs (Njeh 2008), delineation (contouring) uncertainties can
have a large impact on target coverage probabilities and protection of surrounding OAR for
prostate cancer patients. Though site and application-specific, systematic tumor delineation
errors cause an offset from the true target to be hit for treatment (van Herk 2004). Such effect
persists during the treatment course of radiation therapy and is “for some tumor locations
probability the largest factor contributing to geometric inaccuracy” (Weiss and Hess 2003).
Therefore, potential delineation uncertainties should be considered adequately during treatment
planning.

However, this is challenging (Njeh 2008) since the magnitude of delineation

uncertainties depends on many complicated factors including image quality and delineator’s
expertise, training experience and subjective preference.
COP is potentially very useful to account for delineation uncertainties for prostate cancer
patients. It is still ambiguous whether delineation uncertainties can be reduced by advanced
techniques such as IGRT (Njeh et al. 2013). The components of safety margins for target
volumes can be reduced based on improved patient setup and organ variability information
provided by IGRT, but it is inappropriate to overly reduce margins without considering
delineation uncertainties.

The residual errors and probabilities involved in delineation

uncertainties can be compensated by using COP.
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This chapter focuses on the implementation of COP for prostate cancer treatment in the
presence of simulated delineation uncertainties.

The so-called delineation uncertainties are

referring to the difference in voxel locations between the true ROI and the delineated ROI. Like
chapter 5, an introduction of prostate plans and GU model for delineation uncertainties is given
first in the section 6.1 and 6.2. Then the dosimetric effect of delineation uncertainties and
treatment plans using COP and OM, FM techniques will be investigated in the section 6.3 and
6.4.
6.1 Prostate plans
The NKI patient database has been described in detail in section 4.1 and 5.1. Same
reference image sets used in chapter 5 are used per patient. Delineation accuracy is limited by
the CT image resolution is 0.094  0.094  3 mm3. The dose grid is 2  2  2 mm3 for both plan
evaluation and optimization.
With a delineated ROI contour used for treatment planning, delineation uncertainties are
modeled to predict their dosimetric and biologic metric consequences to the possible true ROI in
a virtual treatment course simulation. Here, an average-surface-of-standard-deviation (ASSD)
model is constructed to simulate the delineation uncertainties involved in EBRT for high-risk
prostate cancer.
6.1.1

ASSD model

Inspired by a population-based model of surface segmentation uncertainties for
uncertainty-weighted deformable image registrations (Wu et al. 2010b), the ASSD model is
developed to represent the delineation uncertainties involved in a treatment course. By using
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ASSD, the true ROI volume (with no delineation uncertainties) can be estimated based on the
delineated ROI location on the reference image set of patient database.
The idea of ASSD model is described as follows. In the eye of the tumor, the effect of
delineation uncertainties is very similar to organ motion and setup errors — to introduce
displacement of ROI voxels. The difference between these GUs in terms of voxel displacement
is the voxel-to-voxel distance after displacement. This distance is the same for setup errors,
magnified/demagnified equidistantly for the delineation uncertainties to be modeled here and
non-equidistantly for organ deformable motion. Assume that the possible true ROI surface can
be estimated by expanding or contracting the delineated surface. (The expansion or contraction
corresponds to conservative or aggressive delineators who tend to delineate larger or smaller
ROI contours.) The magnitude of delineation uncertainties for each voxel is scaled by a voxelspecific delineated-to-true-location displacement vector, in analogy of the vector in the DVF
used for the PCA model. This displacement vector for an ROI surface voxel is assumed as a
function of a population-based Gaussian distribution and an individualized variable quantified by
the image intensity gradient on the location of this voxel. The mean of Gaussian distribution is
zero because the delineated ROI surface is assumed to be the best available estimate of the
average of the possible true ROI surfaces. The SD values of the Gaussian distribution in rightleft (RL), posterior-anterior (PA) and superior-interior (SI) are determined empirically based on
literature in Table XIII. The image intensity gradient, or CT gradient in this study, determines
the voxel-specific component of delineation uncertainties caused by different image contrast.
Lower gradient (= poor image contrast) is associated with a larger displacement vector. After the
delineated-to-true-location displacement vectors of the ROI surface voxels are known, the
displacement vectors for an ROI interior voxel is determined by a simple interpolation algorithm
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between two nearest surface voxels to this voxel so that all ROI voxels are deformed in an
equispaced way.
Table XIII: SD values in (mm) of in RL (x), PA (y) and SI (z) direction used in ASSD model for ROIs of
prostate cancer patients

SDy

ROI
CTVprostate
CTVSV

SDx
1.7
1.7

2
2

SDz
2.5
3

bladder
rectum

0.7
1.3

0.7
1.3

3
3

reference
(van Herk 2004)
(Fiorino et al. 1998)
(Rasch, Steenbakkers, and Van Herk 2005)
(Weiss et al. 2010)
(Weiss et al. 2010)

Loop over voxels of
delineated ROI

Calculate CT
gradient
(equation (59))

Yes

Surface
voxel?

No

Find two
nearest surface
voxels

Get FCT
(equation (58))

Interpolate FCT
(equation (60))

End loop
Sample FSD for
each tx course
(equation (57))

Get voxel vector based on
FCT and FSD (equation (56))

Figure 38. Flow of ASSD model to get voxel displacement due to delineation uncertainties. See text for details.
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The detailed workflow of ASSD model is shown in Figure 38. Mathematically, the
displacement vector DT from a delineated (D) to true (T) ROI for a voxel is written as
DT  ( DTx , DTy , DTz )

where DTx , DTy , DTz are RL( x ), PA( y ), SI( z ) components of DT .

(55)

Use r to represent

x, y or z direction generally, then each component of DT is generalized as DTr . For the ROI

voxel with index i , ( DTr )i ,k of treatment course k is assumed to be a function of factors of thw
Gaussian SD ( FCT )r ,k and the CT gradient ( FSD )r ,i in the r direction
( DTr )i ,k  ( FSD )r ,k  ( FCT )r ,i

(56)

( FSD )r ,k varies with the treatment course as

( FSD )r ,k  norminv  ( pRand )k ,0, SDr 

(57)

where norminv() is an inverse standard normal cumulative density function (CDF). ( pRand )k is a
random probability sampled for the treatment course k . 0 and SDr are the Gaussian mean and
the SD in r direction. (As mentioned before, the SDr values of each ROI used in ASSD model
is listed in Table XIII.)

If voxel i is a surface voxel of ROI, its CT-gradient dependent

factor ( FCT )r ,i is written as

( FCT )r ,i 

a
| ( gradCT )r ,i |  a

(58)

where ( gradCT )r ,i is the CT number gradient of voxel i in r component, | | denotes its absolute
value, and a is a normalization factor used to ensure that ( FCT )r ,i ranges from 0 to 1 (Figure 39).
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For all the patients, a = 50 is arbitrarily used here. The voxel-specific ( gradCT )r ,i is obtained
from equation
( gradCT )r ,i 

CTr ,i   CTr ,i 
ri   ri 



CTr ,i   CTr ,i 
2 VoxelSizer

(59)

which is the ratio of CT number difference ( CTr ,i   CTr ,i  ) and position difference ( ri   ri  ) of
neighboring voxels in positive (+) and (negative (-) side of voxel i in r direction. ( ri   ri  ) is
equivalent to 2 times the voxel size in the r direction.

When voxel i is an interior voxel, its

CT-gradient dependent factor ( FCT )r ,i is interpolated from its two nearest surface voxels,
i _ surf  and i _ surf  , in the positive and the negative r direction.

( FCT )r ,i  ( FCT ) r ,i _ surf  +

(( FCT )r ,i _ surf   ( FCT )r ,i _ surf  )
ri _ surf   ri _ surf 

 (ri  ri _ surf  )

(60)

An illustration of FCT -dependent vectors on a transverse slice of rectum is shown in Figure 40.
The different dosimetric effects of delineation uncertainties simulated using FCT -dependent
versus FCT -independent vectors (with FCT =1 as a result of a ~  ) are reflected in the different
pDVHs (Figure 41).

Figure 39. FCT as a function of CT gradient when different parameter a is used.
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Figure 40. CT image slice in transverse plane for rectum (magenta contour) and corresponding F CT
vectors, using a=50.

Figure 41. A patient example of pDVH 95% and 5% using ASSD model using CT-gradient factor:
(thick lines) FCT calculated using a = 50 versus (thin lines) F CT = 1 when a is very large.
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6.2 Decision flow to use COP
With an ASSD model, a prostate plan can be evaluated and optimized to account for
effects of the delineation uncertainties. Like the COP study for deformable organ motions in
chapter 5, a treatment planning decision flow (in Figure 32, page 84) is also used here. This
decision flow is for two concerns: (1) COP may be not essential when dosimetric effect of GUs
is insignificant and (2) how clinically advantageous a COP plan is relative to the PTV-based
plans using empirically determined PTV (FM) and optimized PTV based on target coverage
probability (OM).
The first concern is investigated by calculating the target dose-volume D98 at prescribed
coverage probability 95% (D98,95) on a zero-PTV margin IMRT plan with ASSD model
incorporated. Denote DRx as the prescribed dose 78 Gy for prostate and 66 Gy for seminal
vesicles. By simulating 1000 virtual treatment courses, D98,95 is compared with D98,95,Rx to
determine whether dosimetric effect of modeled delineation uncertainties is insignificant (i.e.,
D98,95  D98,95,Rx). The second concern is researched by optimizing the prostate plans using
COP, OM, FM techniques (whose workflows are shown in Figure 19, page 60). The best plan
among COP, OM and FM plans is determined by comparing their coverage probabilities and P+
values in the presence of modeled delineation uncertainties.
The PTV margins used in the FM plans to account for delineation uncertainties are
different as noted in Figure 19. Here, PTV margins are based on van Herk margin formula
(VHMF): a PTV margin is equivalent to 2.5 SD of systematic errors plus 0.7 SD of random
errors. As delineation uncertainties introduce systematic errors only, the PTV margins M r in
direction r for CTVprostate and CTVSV are simply expressed as
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M r  2.5  SDr

(61)

where SDr values are listed in Table XIII. Accordingly, PTV margins in RL, PA, SI directions
are 4, 5, 6 mm for CTVprostate and 4, 5, 7 mm CTVSV. (The precision of margin setting in
Pinnacle3 is mm.) Therefore, FM uses fixed but non-uniform PTV margins while OM still
optimizes uniform PTV margins based on target coverage probability.
6.3 Results
6.3.1

Dosimetric effects on zero-PTV-margin plans

The dosimetric impact of delineation uncertainties modeled by ASSD model is nonnegligible on target coverage probability for zero-PTV-margin IMRT plans.

Therefore,

replanning using COP, OM or FM is determined as needed to achieve better target coverage
probability. In Figure 42, with 1000 virtual treatment courses simulated, 0/19 zero-PTV-margin
plans achieves DRx for both the CTVprostate and the CTVSV. The resulting dose degradation
%D98,95 calculated based on equation (52) ranges from 3.2-12.2% for CTVprostate and 0-12.9%

for CTVSV. The consequential %DVH98,5-95 is 2.9-13.6% for CTVprostate and 3.8-13.8% for
CTVSV.

The %D98,95 and %DVH98,5-95 values are well correlated (Figure 43) with high

correlation coefficients 0.96 for CTVprostate and 0.83 for CTVSV.
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Figure 42. (a) Percentage degraded dose (%ΔD98,95) and (b) DVH variability (%ΔDVH98,5-95) at prescribed
dose of CTVprostate (red bins) and CTVSV (green bins) for 19 zero-PTV-margin plans with delineation
uncertainties considered (using ASSD model).

Figure 43. Scatter plot of percentage degraded dose (%ΔD 98,95) versus DVH variability (%ΔDVH98,5-95) for
(a) CTVprostate (red dots) and (b) CTVSV (green dots) on 19 zero-PTV-margin plans evaluated with ASSD
model incorporated for each patient.
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The evaluation of zero-PTV-margin plans shows the potential benefit in target coverage
probability by using COP, OM or FM technique. The individual patient pDVH evaluation
results are shown in Figure 51 of Appendix I.c. Based on the average pDVHs shown in Figure 44,
the average impact of delineation uncertainties on OAR volumes are smaller than target volumes.
The Dv,5 criteria are mostly satisfied for OAR volumes. The slack between Dv,5 values and their
objective values, large for bladder and small for rectum, provides room to be exploited for the
increase of target coverage probability.

Figure 44. The average pDVHs 95% (solid) and pDVHs 5% (dashed) evaluated on zero-PTV-margin
plans for 19 high-risk prostate cancer patients for anatomies CTVprostate (prostate) (red), CTVSV
(green), bladder (orange) and rectum (magenta) with optimization objectives (triangle markers). The
ASSD model is incorporated to show the dosimetric consequence of delineation uncertainties for
prostate cancer patients.

6.3.2

COP plans vs. OM plans vs. FM plans

Among the COP, OM, FM plans generated for each patient, either (11/19) OM plan or
(8/19) COP plans are preferred, as Table XIV shows. For the 8 preferred COP plans and the 11
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best OM plans, the clinical benefit relative to FM plans are mostly in OAR sparing: 2/8 COP
plans and 3/11 OM plans improve target D98,95 value while 6/8 COP and 8/11 OM plans achieve
better OAR sparing. When COP and OM compete with each other, COP is more likely to
compromise the target D98,95 value as a result of balancing the weighted OAR objectives. Only
2/8 COP plans (in contrast of 9/11 OM plans) have better target coverage probability while 6/8
COP plans (compared with 2/11 OM plans) gain P+ values. The relative advantages between
three plans are patient-specific. The pDVH comparison of each individual patient is shown in
Figure 52 of Appendix I.d.
Table XIV . Patient ID, percentage target dose degradation %ΔD98,95 for prostate (P) and seminal vesicles (S),
the optimized PTV margins obtained by OM technique, and best planning technique and its gain relative to
the other two plans in terms of target dose coverage(D 98,95) and probability of complication free control P+.
Patient with */ † / ‡ are those COP / OM / FM plans that fails to achieve target D98,95
ID
A*
B†‡
C
D*‡
E
F*
G*
H
I*‡
J*
K*
L*†‡
M
N
O
P
Q
R*‡
S*

%ΔD98,95(%)
P: 7.4 S:12.9
P: 4.1 S:7.1
P: 7.9 S: 5.8
P: 7.9 S: 10.0
P: 4.9 S: 4.2
P: 3.2 S: 0.0
P: 4.2 S: 0.0
P: 6.7 S: 0.0
P: 12.2 S: 3.6
P: 6.8 S: 4.3
P: 6.8 S: 3.3
P: 5.4 S: 9.2
P: 5.8 S: 4.7
P: 8.0 S: 3.6
P: 4.2 S: 2.3
P: 4.7 S: 4.0
P: 3.8 S: 5.4
P: 6.0 S: 3.6
P: 3.4 S: 2.8

OM PTV (mm)
P: 3 S: 2
P: 5 S: 2
P: 4 S: 3
P: 3 S: 2
P: 3 S: 2
P: 2 S: 2
P: 3 S: 0
P: 3 S: 2
P: 5 S: 2
P: 5 S: 2
P: 3 S: 3
P: 5 S: 2
P: 5 S: 2
P: 3 S: 2
P: 4 S: 3
P: 3 S: 2
P: 3 S: 2
P: 5 S: 4
P: 2 S: 2

best plan
OM
COP
COP
OM
OM
OM
OM
COP
OM
OM
OM
COP
COP
COP
COP
COP
OM
OM
OM

Gain relative to the other plans
COP (target D98,95)
FM (+6.4% P+)
OM (target D98,95)
FM (target D98,95)
OM (+4.8% P+)
FM (+9.2% P+)
COP (target D98,95)
FM (target D98,95)
COP (+1% P+)
FM (+7.1% P+)
COP (target D98,95)
FM (+19.6% P+)
COP (target D98,95)
FM (+10.8% P+)
OM (+6.5% P+)
FM (+12.6% P+)
COP (target D98,95)
FM (target D98,95)
COP (target D98,95)
FM (+1.9% P+)
COP (target D98,95)
FM (+7.9% P+)
OM (target D98,95)
FM (target D98,95)
OM (+13.4 P+)
FM (+14.4% P+)
OM (+5.0 P+)
FM (+16.1% P+)
OM (+5.7% P+)
FM (+8.6% P+)
OM (+7.0% P+)
FM (+16.4% P+)
COP (+0.2% P+)
FM (+10.4% P+)
COP (target D98,95)
FM (target D98,95)
COP (target D98,95)
FM (+5.8% P+)

As to the target coverage probabilities, 9/19 COP plans, 17/19 OM plans and 14/19 FM
plans meet the optimization criteria at D98,95,Rx, but the dose degradation %ΔD98,95 values for
CTVprostate and CTVSV are small. For the CTVprostate of COP plans, the maximum %ΔD98,95 is less
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than 3% and %ΔD98,95 of 7/10 COP plans is smaller than 0.3%. For CTVSV, only 2/10 COP
plans fail to achieve the prescribed D98,95. For 2/19 OM plans with a degraded target D98,95, one
has CTVprostate %ΔD98,95 = 0.3% and the other has CTVSV %ΔD98,95 = 0.8%. For FM plans
using VHMF-based margins, CTVprostate D98,95 fails to meet the criterion in 5/19 plans, with
%ΔD98,95 less than 0.9% , while CTVSV D98,95 on all FM plans is larger than D98,95,Rx.
For CTVprostate, the VHMF-based margin does not guarantee that 90% (here, > 17/19) of
patients in the population receive a minimum cumulative CTV dose of at least the prescribed
dose at 95% coverage probability.
On a population-based comparison between COP, OM and FM plans in Figure 45, COP
maximally satisfies bladder and rectum 5% coverage probability-based limits while ensuring
target coverage probability comparable to plans using OM and FM. The comparable target
coverage probability is achieved by taking advantages of OAR Dv,5 slack in lower dose region
(e.g., <65 Gy for bladder and <45 Gy for rectum). Therefore, the target dose at prescribed
coverage that is compromised in the high dose region of an OAR is reasonably increased in the
low dose region within the OAR tolerance. As to PTV margin-based planning, OM is better than
FM in terms of sparing more bladder and rectal dose and achieving more desirable target
coverage probability. The fixed PTV margin based on van Herk formula is often oversized for
CTVSV and suboptimal for CTVprostate, which causes excessive dose delivered to OARs, as
indicated by higher Dv,5 values of FM plans in the high dose region (e.g., > 70 Gy) . To sum up
these results, even in the simplest uniform style, the patient-specific margins optimized using
OM are helpful to create more robust plans than those developed with VHMF-based margins.
Relative to the OM-based margins, the dosimetric margins generated by COP can further reduce
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excessive OAR dose in the high dose region to efficiently achieving acceptable target coverage
probability.

Figure 45. For a population-based comparison, the average PDVHs of (upper) COP vs. OM plans and
(lower) OM vs. FM plans to account for delineation uncertainties. For target structures CTV prostate and
CTVSV, pDVH are of 95% to show the lower bound of target dose-volume metric values of 95% chances.
For OAR structures bladder and rectum, pDVH are of 5% to show the upper bound of OAR dose-volume
metric values of 95% chances.
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6.4 Conclusions
This chapter described the dosimetric effect of patient-specific delineation uncertainties
(via an ASSD model) on 19 patients and the implementation of COP with the ASSD model
incorporated. For the purpose of evaluating the clinical benefit of COP, the ASSD model is also
incorporated into plan evaluation and OM technique for planning comparison.
The dosimetric effect of delineation uncertainties on 19 zero-PTV-margin plans are not
insignificant, so the treatment replanning using COP, OM and FM techniques is performed.
Compared with FM technique that uses empirical fixed PTV margins for each patient, COP or
OM techniques result in either better achieved target dose coverage or less toxicity of normal
tissues because of using coverage-probability metrics as optimization criteria. The relative
advantage between COP and OM are patient-specific. In general, COP shows a clinical benefit
relative to OM in efficiently reducing excessive OAR dose in the high dose region while
maintaining acceptable target coverage probability.
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7

Discussion, conclusions and future directions

This chapter serves a summary of the clinical value of COP in terms of multi-fractional
EBRT treatment for high-risk prostate cancer (7.1) and future directions to further extend usage
of COP, especially for clinical application (7.2).
7.1 Discussion and Conclusions of COP studies
7.1.1

Discussion

For multi-fractional EBRT treatment of high-risk prostate cancer, COP has been studied
to account for two GUs, deformable organ motions (chapter 5) and delineation uncertainties
(chapter 6), respectively. Because of the non-negligible dosimetric consequences, each of the
two GUs has been modeled and incorporated into the probabilistic optimization/evaluation
process to perform/compare treatment techniques — COP and two margin-based treatment
planning techniques, OM and FM. The results show that the beneficial dosimetric consequences
gained from COP is limited for deformable motions but promising for delineation uncertianties.
The goal of COP, OM and FM is to achieve a desirable treatment outcome by creating a
treatment plan dose distribution that can absorb ROI GUs through the whole treatment course.
COP directly optimizes the dose distribution based on the dosimetric margin incorporating GU
models evaluated in possible virtual treatment courses, while both OM and FM are based on a
pre-defined surrogate volume PTV. PTV size in FM is empirally determined and in OM is
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optimized based on target coverage probabiltiy. FM represents the conventional clinical method
which is convenient to be practiced clinically but faces a fundamental problem of how to
determine the optimal PTV margins tailored to each patient’s characteristics. OM represents a
simple form of coverage-probability based treatment planning to optimize patient-specific PTV
margins. The optimized PTV margins are uniform, without being shaved for OARs. OM and
FM are “lower-level” treatment planning techiniques compared with COP and are designed to
determine the relative benefit and cost of COP.

The monitor unit perfraction after plan

optimization using COP, OM or FM techinqiue when accomodating deformable motions or
delineation uncertainties is listed in Table XV. Larger number indicate an increased number of
segments neededfor delivery. In most cases, OM plan is least complex among the three.
Table XV. Monitor unit per fraction for COP, OM or FM plan for patients with ID A to S when
accommodating deformable motions (modeled by PCA) or delineation uncertainties (modeled by ASSD).

ID
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S

COP
483
448
636
531
489
401
406
361
440
537
478
565
555
541
434
441
552
476
405

w/ PCA
OM
422
580
594
491
487
376
385
398
746
563
637
537
500
485
398
421
537
505
410

FM
444
536
631
515
503
417
430
464
476
501
634
579
592
515
480
503
579
587
445
111

COP
572
662
601
552
589
442
401
400
477
498
544
559
601
461
441
451
600
567
417

w/ ASSD
OM
412
524
559
473
458
379
386
377
449
481
524
534
489
442
442
435
503
536
404

FM
444
550
629
505
500
459
412
421
460
503
600
508
500
505
448
441
577
543
432

It is inappropriate to state for granted that OM and FM are a subset of COP as
implemented in this dissertation. The dose distribution of COP can be very different from OM
and FM. As Figure 46 shows, the 0 Gy isodose difference surface between OM and FM plans
are around CTVprostate volume while this is not the case for the dose distribution difference
between COP and FM plans. In this example, COP tends to increase dose to the non-OAR
region adjacent to the target to ensure target coverage and OAR sparing. The biggest difference
between OM, FM and COP is that COP considers coverage probaiblity for both the CTVs and
the OARs during optimization, while the PTV margin sizes in OM and FM techniques are
determined without considering the OAR criteria. The modification of the DM during COP
optimization is constrained by the OAR probablistic critera while PTV in OM can be
continuously enlarged to meet the target coverage constraint. It is very normal that the DMs of
COP can only be expanded within a limited range due to the competing target and OAR
objectives. (One example is illustrated in Figure 47, where COP result in smaller DM between
CTVprostate and TV 78Gy in the region of bladder.) Starting from a zero-PTV-margin plan where
no PTV-OAR-overlapping volume is involved, COP may face the dilemma that how to expand
dosimetric margins for the low target D98,95 in the presence of some high OAR Dv,5 values. (See
rectal pDVH 5% and CTVprostate or CTVSV pDVH 95% in Figure 33 on page 86 and Figure 44 on
page 105). As a result, to spare more OAR dose, COP often has to compromise a certain level
of target coverage probability in order to minimize the composite objective value. This is why
CTVprostate or CTVSV in COP often fails the D98,95,Rx criteria after balancing the conflicts of CTV
and OAR coverage. In contrast, thanks to the large range of PTV margin size in OM and FM,
target D98,95,Rx of OM and FM plans are much easier to achieve.
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As long as no tough

competition between PTV and OAR involved (illustrated in Figure 36, page 91), the target
D98,95 ≥ D98,95,Rx as a result of resonably large PTV margins is possible.

Figure 46. The dose distribution difference as COP minus FM (left column) and OM minus FM (right
column) in SI, RL and PA slice for patient S when deformable motions are accommodated. ROIs
displayed as colorwash are CTVprostate (red), CTVSV (green), bladder (yellow) and rectum (magenta). The
dose distribution around CTVprostate in COP plan is quite different from that on OM and FM plans.
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Figure 47. Dose distribution of COP versus OM versus FM plans on one slice for patient H when
delineation uncertainties are considered. The thick isodose surface are TVs for of 78Gy (seashell) for
CTVprostate (red colorwash) and of 66Gy (aquamarine) for CTV SV (green colorwash). The yellow and
magenta colorwash are bladder and rectum. The other isodose surfaces are 75 Gy (maroon), 69 Gy
(slateblue) and 57 Gy (lightblue). The smaller DMs of COP plan in some directions due to the
compromise of OAR are sometimes more likely to fail to achieve the target coverage.

When treatment for a high-risk prostate cancer patient is planned, it is inadequate to use
empirical PTV margins without considering the patient-specific response to coverage
probability. This has been proved for setup errors (Gordon et al. 2007, Gordon and Siebers
2009, Xu et al. 2011). The intrafraction motions can be excluded due to their insignificant
dosimetric effect. (Langen et al. 2012) For interfraction deformable motion and delineation
uncertainties in this dissertation, the PTV margins determined by a published work (Mutanga et
al. 2011) or VHMF fail to generate desirable plans that are immune to the influence of GUs.
Coverage probability is a useful metric for treatment plan optimization. In general, the
planning techinques that considers coverage probability (COP or OM) are more beneficial to
account for GUs than FM. For setup errors, the advantages of COP and OM relative to VHMFbased FM have been investigated via two published works. (Gordon and Siebers 2009, Gordon
et al. 2010)

The improved target dose and/or reduced OAR dose at specified coverage

probability were pronouced compared with the corresponding VHMF-FM plans for
intermiediate-risk prostate cancer patients. Using OM for translation setup errors following
Gaussian distribution with systematic and random SD 2 mm, the total volume of normal tissue
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receiving dose higher than 65 Gy was reduced on average by 19.3% or about 48 cc.(Gordon and
Siebers 2009) Using COP for translation setup errors following Gaussian distribution with
systematic and random SD 3mm, rectal NTCP got reduced by 10%.

In this dissertation,

COP/OM also present dosimetric advantages relative to FM when compensating PCA modeled
interfraction deformable organ motion and ASSD-modeled delineation uncertainties (Table XI
and Table XIV). These relative advantages reveal the inadequacy of using population-based
empirical margins and emphasize the the necessity and potential of coverage-based treatment
planning to account for all types of GUs.
For the parameters used in this study, the benefit of COP relative to OM is patientspecific and varies with different GUs. In the study to account for deformable motions, OM is
more likely to be preferrable than COP in most patient cases because the better achieved target
coverage probability with comparable OAR sparing. (Table XI, page 89) In at least half of these
cases, COP compromises target D98,95 (with dose degradation more than 2%) to ensure OAR
(especially rectal) dose sparing. Whether COP is advantageous over OM for these cases when
COP target coverage is given a higher priority (weight) is the subject of future study. The
neccessity for COP and OM plans may be reduced by advanced IGART strategies, where the
reduced alignment errors and accomodation for deformable motions via adaptive corrections
result in less stringent target-OAR tradeoff and better treatment outcomes. In the study to
account for delineation uncertainties, COP shows promising potential in efficiently sparing both
bladder and rectal dose. (Table XIV, page 106) The p+ gain is 5.5% on average and up to 18.7%
relative to OM plans. (If little compromise of target coverage probability (e.g., 1%) is acceptable,
at least 3 more COP plans other than OM plans become the best plans.) This clinical benefit of
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COP in terms of delineation uncertainties is probably significant since the advanced IGART
strategies are of limited usefulness for reducing delineation uncertainites. (Njeh et al. 2013)
Dose delivered to lymph nodes (as treatment target) and small bowel (as dose limiting
OAR) may show more benefit of COP related to OM and FM, though these two structures are
not included in the prostate cancer studies of this dissertation. To date, a growing body of data
have suggested that IMRT provides greater advantages over conventional and 3DCRT for pelvic
nodes irradiation than localized prostate irradiation, when attempting sparing surrounding normal
tissues. (Shih et al. 2005, Wang-Chesebro et al. 2006) This reveals the complex geometry of
lymph nodes and the necessity of more conformal radiation, which indiates the greater sensitivity
of lymph nodes to GUs.

For the small bowel, the risk of irradiated toxicity may be boosted

when some dose limits (Kavanagh et al. 2010) are exceeded as a result of large PTV margins of
CTVprostate or CTVSV used in OM or FM. COP may result in more desirable lymph nodes
coverage or small bowel sparing by savvily creating an optimized DM.
The clnical value of COP may also change with many factors. COP is expected to be
more beneficial when e.g., using proton therapy and/or treating cites of some stage that are more
likely to require non-uniform margins, like the findings for the PTP techniques reported by the
researchers in Massachusetts General Hospital and Harvard Medical School.(Unkelbach et al.
2007, 2009)

The advantage of COP may be reduced by e.g., implementing more advanced

IGART strategies and/or planning on structures which are less senstive to dose. Different
treatment protocols with loose or tight criteria may affect the outcome of COP too. Some of
these factors will be discussed later for the future COP studies.
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7.1.2

Conclusions

In order to ensure if a treatment plan is immune to the degraded effects of GUs, coverage
probability is a critical metric to be calculated and compared during planning optimization and
evaluation process. The dosimetric effects of deformable organ motion and delineation
uncertainties involved in high-risk prostate cancer treatment are not insignificant in terms of the
specified target coverage probability 95%.
For high-risk prostate cancer patients treated by multi-fractional EBRT, treatment
planning techniques (COP and OM) based on coverage probability metrics shows dosimetric
advantages relative to conventional margin-based techniques — FM. Empirical PTV margins
face the risk of undesirable target coverage probability and/or excessive dose to surrounding
OAR.
In this dissertation, the clinical value of COP is limited to compensate deformable organ
motions due to the frequently compromised target coverage probabilities for the concern of
normal tissue dose sparing. (caveat page 115) For the objective weights and criteria used here,
the OM technique and more advanced clinical strategies can provide preferred solutions to
compensate and/or reduce the dosimetric effect of deformable organ motions for high-risk
prostate cancer patients.
The clinical role of COP is potentially significant in terms of delineation uncertainties.
COP spares excessive OAR dose in high dose regions while exploiting the slack in low dose
regions within the tolerance to maintain acceptable target coverage probability. (caveat page
115) Compared to less decent OM plans and IGART strategies, COP offers a good solution to
adequately consider delineation uncertainties for treatment planning.
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7.2 Future directions of COP studies
7.2.1

Realistic clinical implementation issues

COP still has hurdles to overcome before being implemented in clinical practice. These
hurdles can be investigated in the future to improve the clinical feasibility of COP.
First, COP may fail to achieve target coverage probability due to the OAR dose-limiting
criteria. It may be helpful to solve this potential problem by increasing the objective weights for
the target criteria. One possible way is to utilize the “constraint” function in Pinnacle3 to make
the target objective weight effectively infinitely large. Another possible way is to reduce the
relative OAR objective weights in the hope that the target dose is less tightened. How to specify
appropriate OAR objective weights adaptive to each patient is an interesting topic for future
research. Inappropriate weight reduction may result in undesirable OAR toxicity, as Figure 48
illustrates.

Figure 48. An example of the pDVHs of the COP plan that uses inappropriately reduced OAR objective
weights (dashed) in the contrast to that uses original OAR objective weights (solid). The pDVHs are of 95%
for CTVprostate (red) and CTVSV (green) and 5% for bladder (orange) and rectum (magenta).
Inappropriately reduced OAR objective weights may result in high OAR dose beyond the tolerance.
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Second, GU models used in COP and the probabilistic planning optimization need
verification and improvement of their representativeness for realistic patient cases. Though the
modeling uncertainties can be absorbed to some extent in the large number of simulated virtual
treatment course, the inadequate GU models may affect COP and probabilistic evaluation. The
PCA model and ASSD model can be tested on a large sample of patient image sets and
differently delineated ROI contours.
Third, for organ anatomical/contour variability between treatment fractions, it is almost
impossible to obtain sufficient patient-specific GU information before treatment planning is
performed.

Thus, without known GU PDFs, COP cannot be used in the initial treatment

planning process. A possible solution is to build a reasonably representative patient-specific GU
model after several (e.g., 5) fractions. With this model, COP can be performed in sequential
fractions and compensate GUs that occur in these fractions.
Fourth, COP is still too slow to be executed in the clinic. For a 50-iteration optimization,
the run time for COP on a 2.93 GHz Quad Core Processor Core i7-870 is 3-4 hours for
deformable organ motions and delineation uncertainties. The run times are based on simulating
100 * 30 virtual treatment fractions on a 3  3  3 mm3 dose grid (for deformable organ motions)
or 1000* 1 virtual treatment fractions for COP on a 2  2  2 mm3 dose grid (for delineation
uncertainties). It is necessary to optimize/parallelize COP code and/ or use more efficient COP
parameters (e.g., fewer treatment course number) to speed up COP.
7.2.2

COP in different IGART strategies

The advanced clinical strategies, such as IGART utilizing daily re-planning (Sharma et
al. Unpublished), may have dosimetric advantages over conventional IMRT for critical
structures without compromising target coverage. When these strategies are clinically practical,
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the future role of COP will become to compensate their residual uncertainties. Some Pinnacle3
plugins have been developed (Appendix II.a) and may be used to simulate different frequencies
of IGART.

Therefore, the residual benefit of COP in different clinical scenarios can be

investigated.
7.2.3

Bladder and rectal wall as OAR for prostate cancer

According to the recommendation of ICRU report 83 (ICRU Report 83 2011), bladder
wall and rectal wall instead their whole volume should be used as the critical OARs for prostate
cancer study. However, delineation of bladder wall and rectal wall is complicated due to poor
image quality for real patient cases, which is limited by the realistic concerns such as imaging
dose constraints, image data size and medical cost.

Inappropriate delineation or image

registration of bladder wall during planning and treatment of EBRT may result in incorrect OAR
dose evaluation. This may lead to suboptimal OAR sparing or missed opportunities for target
coverage due to overrepresentation of the OAR dose during the planning process. As there is no
guidance on how to delineate deformed walls as the filling of hollow organs changes, the base
characteristics of the bladder wall changes as a function of bladder filling was studied using pig
bladders. (See Appendix II.d.) That study concludes that it is adequate to assume a constant
bladder wall volume as the bladder fills/empties (and wall thins/thickens). This assumption can
be used to assist and test wall delineations as well as image registration for multi-fraction EBRT.
For the future prostate cancer studies, wall structures should be involved.
7.2.4

Different treatment sites

The benefit of COP may be more pronounced for the treatment cites other than prostate
cancer. Due to quasi-isotropic anatomical shape of CTVprostate and its quasi-isotropic pattern of
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GUs, uniform PTV margins (e.g., optimized by OM technique) are often good enough to ensure
target coverage probabilities as well as excessive OAR dose sparing. The potential advantages
of dosimetric margins derived in COP equivalent to using non-uniform PTV margins are limited
in prostate cancer cases. Treatment sites with complex tumor shape (e.g., head and neck cancer)
and/or irregular GU pattern (e.g., lung cancer) may have more clinical benefit from COP
techniques.
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Appendix I.

Patient-specific pDVH results of COP studies

a. pDVH evaluation with deformable motion model (PCA) incorporated
For each one of the 19 patients, pDVH 95% and 5% for CTVprostate, CTVSV, bladder and
rectum on a zero-PTV-margin plan are plotted below. The dosimetric effect of deformable organ
motions reflected on the plot is patient-specific.
Though the CTVprostate-centroid is always aligned, none of the patients is immune to the
degradation effect of target coverage due to deformable organ motions.

The target dose

deviation from the objective values at 95% coverage probability can be relatively small (e.g.,
patient G, H, O, P and S) or large (e.g., patient A, D, I, J, L, M and N), but all indicate the
necessity of larger PTV margin or DM to improve the target coverage.
When it comes to the OARs, the rectum is more likely to be overdosed than the bladder.
The rectal dose at 5% coverage probability of more than half patient cases already exceeds the
dose limits before larger margin is used, which shows the potential conflict of rectal sparing and
target coverage improvement. In contrast, the bladder dose at 5% coverage probability is mostly
within the dose tolerance for most patients, except patient B, E, J, O, R whose bladder dose is a
little beyond one or two objective values. The slack between the current bladder dose and the
corresponding bladder dose limits, which is large for more than half of patients, provides room
for margin expansion.
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Figure 49. The patient-specific pDVHs 95% (solid) and pDVHs 5% (dashed) evaluated on zero-PTVmargin plans for patient with ID A to S(continued below) for anatomies CTVprostate (prostate) (red),
CTVSV (green), bladder (orange) and rectum (magenta) with optimization objectives (triangle markers).
The PCA model is incorporated to show the dosimetric consequence of organ deformable motions.
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b. Optimized plan comparison with deformable motion model (PCA) incorporated
For each one of the 19 patients, pDVH 95% for CTVprostate and CTVSV, and pDVH 5%
for bladder and rectum on COP, OM and FM plans are plotted below. The benefit of COP
relative to the other two margin-based planning techniques when accommodating organ
deformable motions is patient-specific. For the patient cases (G, J, K, L, P, R, S) whose COP
plan is preferred, some show the improved target coverage and the others get more decent OAR
sparing. The best case for COP pDVH is patient P, as both target coverage and OAR sparing get
effectively improved. However, advantages brought from COP are more limited for the other
patients. When the COP plan fails to meet the target coverage criteria due to the competing
OAR coverage criteria, the OM plan is more likely to be preferred.
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Figure 50. The pDVHs 95% of CTVprostate (red) and CTVSV (green) and the pDVHs 5% bladder (orange)
and rectum (magenta) for the patient-specific comparison of COP(solid), OM (dashed) and FM (dot) plans
for the patient with ID A to S (continued below), with optimization objectives (triangle markers). The PCA
model is incorporated to show the dosimetric consequence of organ deformable motions.
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c. pDVH evaluation with delineation uncertainties model (ASSD) incorporated
For each one of the 19 patients, pDVH 95% and 5% for CTVprostate, CTVSV, bladder and
rectum on a zero-PTV-margin plan are plotted below. The dosimetric effect of delineation
uncertainties is patient-specific and non-negligible.
As the target dose at 95% coverage probability is more or less degraded from the
objective values, larger PTV margin or DM is needed to improve the target coverage. For
OARs, the rectum is more likely to be overdosed than the bladder. The rectal dose of each
patient at 5% coverage probability exceeds at least one dose limits before margin is used, which
shows the potential conflict of rectal sparing and target coverage improvement. In contrast, the
bladder dose at 5% coverage probability is mostly within the dose tolerance for most patients,
except patient B, I, L, N, R. The slack between the current bladder dose and the corresponding
bladder dose limits, which is large for most patients, provides room for margin expansion.
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Figure 51. The patient-specific pDVHs 95% (solid) and pDVHs 5% (dashed) evaluated on zero-PTVmargin plans for patient with ID A to S(continued below) for anatomies CTVprostate (red), CTVSV (green),
bladder (orange) and rectum (magenta) with optimization objectives (triangle markers). The PCA model is
incorporated to show the dosimetric consequence of organ deformable motions.
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d. Optimized plan comparison with delineation uncertainties model (ASSD) incorporated
For each one of the 19 patients, pDVH 95% for CTVprostate and CTVSV, and pDVH 5%
for bladder and rectum on COP, OM and FM plans are plotted below. When delineation
uncertainties are accommodated, the benefit of COP relative to the other two margin-based
planning techniques is patient-specific. For the patient cases (B, C, H, L, M, N, O, P) whose
COP plan is preferred, most show more decent OAR sparing. The best case for COP pDVH is
patient C, whose dose sparing for bladder and rectum relative to OM and FM pDVHs is most
pronounced. Compared to the study for deformable motions, COP plan is more beneficial when
delineation uncertainties are accommodated.

Figure 52. The pDVHs 95% of CTVprostate (red) and CTVSV (green) and the pDVHs 5% bladder (orange)
and rectum (magenta) for the patient-specific comparison of COP(solid), OM (dashed) and FM (dot) plans
for the patient with ID A to S (continued below), with optimization objectives (triangle markers). The
ASSD model is incorporated to show the dosimetric consequence of delineation uncertainties.
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Appendix II. Related projects

a. Plugins developed for IGART plan evaluation
Three Pinnacle3 plugins have been developed for future IGART plan evaluation. The
plugins are the dynamic libraries to extend the functionality of Pinnacle3.

Each plugin is

responsible for one main step for a complete plan evaluation. First plugin copies a plan created
on one image set to sequential image set(s).

The second plugin does dose mapping and

accumulation. The third plugin calculates metrics such as DVH, EUD, TCP and NTCP. These
plugins can be called by a simple click on a script list once they are loaded in the TPS.
The first plugin is named as “HXCopyBeamComputeDose” (HXCBCD). The workflow
of HXCBCD for plan copying is summarized in the Table XVI. Three things need to be noted
here. First, the treatment plan is copied by matching the centroid of prostate, assuming that
prostate is reliably tracked before being treated in each fraction. Second, a plan is copied mainly
by copying beam settings and recomputing the dose. This can be simplified as copying dose
only, according to the assumption of dose-shift variance. The dose difference between dose
copying and beam copying is within 2%. (Sharma et al. 2012)

Third, some functions that have

been extended from HXCBCD are not included in the Table XVI. An example is that the
optimization criteria (Table III, page 22) for either COP or PTV-based plans based on VCU or
other protocols can be loaded by calling the functions in HXCBCD plugin.
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Table XVI. Workflow of HXCBCD plugin for copying plan to treatment fractions.
Prior manipulation


Delete extra trials, beams, beam iso-center for resetting (No more included)
TPS would crash when executing this task. The reason is unknown. Scripts are written to execute this
task.



Check the image set name for each trial in the TrialList.
Errors will be returned if any trial for treatment shares the same reference image set.

On the reference trial associated with the reference image set


Delete beams on reference trial and add seven beams for IMRT
Default beam settings:
I. Machine 21EX;
II. Energy 18 MV;
III. Beam type: Static;
IV Gantry Angle:
V: Isocenter: GTV(prostate) centroid
VI Beam Collimator: 90;
VII: Initialize and unlock Beam Weight: ~14.28 ~ (100/7);
VIII: Set dose prescription as 1.80 Gy/fraction * 44 fractions.)



Load criteria for optimization
Default criteria protocol: RTOG 0126
Two structures are created if inexistent: PTV = GTV1+1cm margin. LNT = GTV1 ring 2-4 cm.
This is optional for other protocol.



Perform IMRT optimization
I. Set dose grid for dose calculation: as large to cover skin
II. IMRT setting: DMPO, Allow Jaw Motion, Split beam if necessary

On each fractional trial that is associated with fractional image set


Set beam isocenter as the centroid of GTV on this image set



Delete beams and copy the beam settings from the reference image set
I. Dose grid
II. Beam weight
III. Beam monitor unit (MU) after optimization



Compute copied beams
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The second plugin is named as “HXVolumeWarpingPlugin” (HXVWP).

HXVWP

performs dose mapping between reference image set and fractional image sets in the region
within the dose grid and create an accumulated dose on the reference image. (Readers are
referred to Figure 26, page 74 for a graphical illustration.) The input data for this plugin are the
DVF from the reference to the fractional image set dose. Based on this DVF, any voxel within a
pre-defined dose grid on the reference image set can find its corresponding coordinate on the
fractional image set. (As the resolution of dose grid and DVF may be different, interpolation
calculations may be involved in the process.) The voxel dose on the fractional image set is read
and then mapped back to the reference image set. Often, the actual delivered dose distribution is
degraded compared with the static dose distribution planned on the reference image set. The
accuracy of the dose mapping algorithm remains a concern for this tool. Though many test cases
(e.g, on a homogeneous or heterogeneous phantom) have been carried out, verification of dose
mapping for real patient is challenging due to no metric being upon which to base the accuracy
of the dose accumulation. (Schultheiss et al. 2012)
Compared to the other plugins, HXVWP has been developed to be more user-friendly.
Figure 53 shows the graphical user interface (GUI) of HXVWP. Users can select dose mapping
algorithm, DVF type according to their need. An attached application called “TrialStoreEditor”
can record the dose mapping parameters.
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Figure 53. Interfraces of the GUI to launch HXVWP and the application to store the information of dose
mapping. Note the mapping type for HXVWP is Plugin-based RCF DoseMapping. (Copyright JV Siebers
2011©)

The third plugin is named as “HXRoiDVHPlugin” (HXRDP). This plugin first calculates
a DVH (for either physical dose or BED) and then transfers the DVH to biological metrics EUD,
TCP and NTCP. A workflow of this plugin is shown in Figure 54. The equations and their
parameters for biological metric calculation are those mentioned in chapter 3.

Figure 54. Workflow of DVH calculation of HXRDP
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b. Coverage estimates vs. dosimetric margin distribution sampling parameters
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c. Interobserver contour variations with respect to margin size
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d. Bladder wall characteristics
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